Pilocytic astrocytoma is a WHO grade I, slow-growing, well-circumscribed cerebellar tumor most common in children, often presenting as a cystic mass with an enhancing mural nodule.

Pilocytic Astrocytoma (PA)

Pilocytic astrocytoma (PA) is a WHO CNS Grade 1 (the lowest grade), slow-growing, well-circumscribed, typically cystic glial neoplasm arising from astrocytes. The name itself is instructive:

"Pilo-" → from Latin pilus = "hair" — referring to the bipolar, hair-like (piloid) processes of the tumour cells seen under microscopy
"Astro-" → from Greek astron = "star" — referring to the star-shaped astrocyte, the cell of origin
"-cytoma" → from Greek kytos = "cell" + -oma = "tumour"

So the name literally means: "a tumour of star-shaped cells with hair-like projections."

PA is the most common astrocytoma in children and is classified as Grade 1 (WHO) ^[1]^[2]

It is biologically benign: rarely invasive and rarely undergoes malignant transformation into a more aggressive tumour ^[1]^[2]. It carries an excellent long-term prognosis, with > 95% 10-year survival following gross total resection.

Key Conceptual Point

In intracranial neoplasia, "malignancy" is different from extracranial tumours. A histologically benign-looking tumour can still cause devastating neurological damage if it occupies a functionally critical or surgically inaccessible location (e.g., optic chiasm, hypothalamus, brainstem). Conversely, even histologically malignant brain tumours rarely metastasize extracranially because the brain lacks conventional lymphatic drainage. Therefore, TNM staging is not useful for primary brain tumours ^[3].

2. Epidemiology

Most common primary CNS tumour of childhood — accounts for approximately 15–20% of all paediatric brain tumours and ~5–6% of all gliomas across all ages
Annual incidence: approximately 0.8–1.0 per 100,000 in children (< 15 years)
Peak incidence: 5–14 years of age (median ~6–8 years)
Second smaller peak in young adults (20–24 years), though much less common in adults overall
In children: ~40% of brain tumours are infratentorial (posterior fossa), and PA is the most common posterior fossa tumour in this age group alongside medulloblastoma ^[3]

Slight male predominance (~1.1–1.3:1 M:F) though some series report near-equal sex distribution
No significant racial or geographic predilection, but data from Hong Kong and East Asia suggest similar incidence patterns to Western populations
Primary brain tumours overall are rare (6/100,000 per year) ^[3]; PA constitutes a meaningful proportion of the paediatric subset

In Hong Kong, paediatric CNS tumours represent the second most common childhood malignancy after leukaemia
PA is among the most common paediatric CNS tumours encountered at Queen Mary Hospital and Prince of Wales Hospital neurosurgery units
The Hong Kong Children's Cancer Registry data mirrors international patterns for PA epidemiology

3. Risk Factors

The single most significant risk factor for PA is Neurofibromatosis Type 1 (NF1):

Optic pathway glioma (OPG): affects 15% of NF1 patients ≤ 6 years old, rarely occurs in older patients ^[4]
Pathology: typically low-grade pilocytic astrocytoma ^[4]
Site: anywhere along the optic nerve, chiasm, optic tract and optic radiation ^[4]
Complications: visual loss, premature or delayed puberty (if involving hypothalamus) ^[4]
NF1 is caused by mutation in the NF1 gene (17q11.2) encoding neurofibromin, a RAS-GAP (GTPase-activating protein) → loss of neurofibromin → constitutive activation of the RAS/MAPK/ERK pathway → uncontrolled cell proliferation ^[4]

High Yield – NF1 and Optic Pathway Glioma

If you see a child < 6 years with a tumour along the optic pathway, think NF1. The vast majority of optic pathway gliomas in NF1 are pilocytic astrocytomas. NF1-associated OPGs generally carry a better prognosis than sporadic OPGs — many remain indolent and do not require treatment. Screening involves annual ophthalmological assessment in NF1 children.

Other syndromic associations (much rarer):

Tuberous Sclerosis Complex (TSC): associated with subependymal giant cell astrocytoma (SEGA) — another WHO Grade 1 astrocytoma, but distinct from PA
Li-Fraumeni syndrome (TP53 germline mutation): more associated with high-grade gliomas, but marginally increases general brain tumour risk

The vast majority of PA cases (~85%) are sporadic (no identifiable syndrome)
No clearly established environmental risk factors (unlike some adult gliomas)
Prior cranial irradiation (e.g., for childhood leukaemia CNS prophylaxis) increases the risk of secondary gliomas, though these tend to be higher grade

Mobile phone use, electromagnetic fields, dietary factors — no proven association with PA

4. Anatomy and Function – Relevant Neuroanatomy

Understanding the anatomy is critical because the location of the PA determines the clinical presentation, surgical approach, and prognosis.

Classical site is cerebellum but can occur anywhere in CNS including hypothalamus, optic nerve and chiasmal region ^[1]^[2]

Site	Approximate Frequency	Why It Matters
Cerebellum (most common)	~60% in children	Causes ataxia, raised ICP from 4th ventricle obstruction
Optic pathway / Hypothalamus	~25–30%	Especially in NF1; causes visual loss, endocrinopathy
Brainstem (e.g., dorsal midbrain, cervicomedullary junction)	~10%	Cranial nerve palsies, long tract signs
Cerebral hemispheres	~5–10% (more common in adults)	Seizures, focal deficits
Spinal cord	Rare	Myelopathy, back pain

The cerebellum lies in the posterior fossa, behind the brainstem, beneath the tentorium cerebelli:

Cerebellar vermis (midline): coordinates truncal/axial movements → lesions cause truncal ataxia (wide-based gait, inability to sit upright)
Cerebellar hemispheres (lateral): coordinate ipsilateral limb movements → lesions cause appendicular ataxia (past-pointing, dysmetria, intention tremor on the same side as the lesion)
4th ventricle: lies immediately anterior to the cerebellum → posterior fossa tumours (PA, medulloblastoma, ependymoma) can compress or obstruct the 4th ventricle → obstructive (non-communicating) hydrocephalus → raised ICP

Why does PA in the cerebellum cause raised ICP? The CSF pathway flows: lateral ventricles → foramen of Monro → 3rd ventricle → cerebral aqueduct (of Sylvius) → 4th ventricle → foramina of Luschka and Magendie → subarachnoid space. A cerebellar PA can compress the 4th ventricle or block the aqueduct, obstructing CSF flow → upstream dilatation of ventricles → raised intracranial pressure.

Optic nerve → optic chiasm (where nasal fibres decussate) → optic tract → lateral geniculate nucleus → optic radiation → visual cortex
A PA along this pathway can produce:
- Unilateral visual loss / relative afferent pupillary defect (RAPD) — if optic nerve involved
- Bitemporal hemianopia — if chiasm compressed
- Homonymous hemianopia — if optic tract involved
- Proptosis — if intraorbital optic nerve involved (expanding mass pushes the globe forward)

PA involving the hypothalamus can disrupt:
- GnRH → precocious puberty (stimulation) or delayed puberty (destruction)
- GHRH / GH axis → growth failure
- CRH, TRH, ADH → multiple endocrine dysfunctions
- Satiety centre → diencephalic syndrome in infants (paradoxical emaciation despite adequate caloric intake) or obesity

5. Etiology and Pathophysiology

5.1 Molecular Pathogenesis — The MAPK Pathway is Central

The defining molecular feature of PA is constitutive activation of the RAS-MAPK (mitogen-activated protein kinase) signalling pathway. This single pathway drives nearly all PAs:

Growth factor → Receptor tyrosine kinase → RAS → RAF → MEK → ERK → Cell proliferation

BRAF-KIAA1549 fusion (tandem duplication on chromosome 7q34):

Found in ~70–80% of cerebellar PAs
Creates a constitutively active BRAF kinase that cannot be auto-inhibited
Mechanism: the N-terminal regulatory domain of BRAF is lost in the fusion, so the kinase domain is permanently "switched on" → continuous MEK/ERK signalling → cell proliferation
This is highly specific to PA and is diagnostically useful

BRAF V600E point mutation:

Less common in PA (~5–10%), more common in pleomorphic xanthoastrocytoma and ganglioglioma
A valine-to-glutamate substitution at codon 600 → constitutive kinase activation
PAs with BRAF V600E may have a slightly different biology and can be targeted with BRAF inhibitors (e.g., dabrafenib) — this is increasingly important therapeutically in 2025–2026

NF1 gene encodes neurofibromin, which is a RAS-GAP (GTPase-activating protein)
Neurofibromin normally inactivates RAS by accelerating the hydrolysis of RAS-GTP to RAS-GDP
Loss of NF1 → RAS stays in the active GTP-bound form → constitutive MAPK pathway activation → cell proliferation
Two-hit hypothesis: NF1 patients inherit one defective copy (germline mutation); somatic loss of the remaining allele in a susceptible glial cell initiates tumorigenesis

FGFR1 mutations/fusions (more common in midline/diencephalic PA)
NTRK family fusions (rare, but druggable with larotrectinib/entrectinib)
KRAS mutations (rare)

Why Does This Matter Clinically?

The near-universal involvement of the MAPK pathway in PA has two implications: (1) Diagnostic — BRAF-KIAA1549 fusion is nearly pathognomonic for cerebellar PA; (2) Therapeutic — MEK inhibitors (selumetinib, trametinib) and BRAF inhibitors (dabrafenib) are now used as first-line medical therapy for progressive/unresectable PA, representing a paradigm shift from traditional chemotherapy (especially for optic pathway gliomas). The 2024 WHO guidelines and SIOPE/COG protocols reflect this change.

A fascinating biological concept explaining why PA is low-grade:

The same MAPK overactivation that drives initial proliferation eventually triggers oncogene-induced senescence (OIS) — a permanent cell-cycle arrest
This is mediated by upregulation of p16^INK4a and p21 (cell-cycle inhibitors)
This explains why PA:
- Grows slowly after initial expansion
- Rarely undergoes malignant transformation ^[1]^[2]
- Can spontaneously stabilize or even regress (especially NF1-associated OPG)
Loss of the senescence pathway (e.g., CDKN2A/p16 deletion) is associated with the rare instances of PA progressing to a higher grade

Feature	Pilocytic Astrocytoma	High-Grade Glioma (e.g., GBM)
WHO Grade	1	4
Growth pattern	Well-circumscribed, cystic	Diffusely infiltrating
Key molecular driver	BRAF-KIAA1549 fusion	IDH-wildtype, TERT promoter, EGFR amplification
Invasiveness	Rarely invasive ^[1]^[2]	Highly invasive
Malignant transformation	Rare ^[1]^[2]	N/A (already malignant)
Metastatic potential	Low; small proportion with meningeal spread, particularly optic path region ^[1]^[2]	Low extracranial; high local recurrence
Senescence	OIS present	OIS pathways lost
Prognosis	Excellent (> 95% 10-year OS)	Dismal (~15 months median survival)

6. Classification

WHO classification of astrocytomas: ^[1]^[2]

Grade I = Pilocytic astrocytoma (PA) / Subependymal giant cell tumours (SGCTs)

Grade II = Fibrillary infiltrating astrocytoma / Pilomyxoid astrocytoma

Grade III = Anaplastic astrocytoma

Grade IV = Glioblastoma multiforme (GBM)

Low-grade astrocytoma (LGAs) = Grade I and II; High-grade astrocytoma (HGAs) = Grade III and IV

High Yield – 2021 WHO CNS5 Update

The 2021 WHO Classification of CNS Tumours (5th edition, "CNS5") introduced major changes to glioma classification by integrating molecular markers. However, pilocytic astrocytoma remains WHO Grade 1 and is now specifically classified under "Circumscribed astrocytic gliomas" (as opposed to "Diffuse astrocytic gliomas" which include IDH-mutant astrocytomas and IDH-wildtype glioblastoma). The key distinction: PA is circumscribed/localized, not diffusely infiltrating. The new grading uses Arabic numerals (Grade 1, 2, 3, 4) instead of Roman numerals (Grade I, II, III, IV), though many lecture slides still use the older Roman numeral notation.

Location	Typical Age	Association	Prognosis
Cerebellar (most common)	Children 5–14y	Sporadic; BRAF-KIAA1549 fusion in ~80%	Excellent — GTR often curative
Optic pathway/hypothalamic	Younger children (< 6y)	NF1 in ~50%	Good but more complex; often cannot resect
Brainstem	Any age	Sporadic	Intermediate — depends on exact location
Cerebral hemisphere	Older children / young adults	Sporadic; higher rate of BRAF V600E	Good with resection
Spinal cord	Any age	Sporadic	Good with resection

Previously considered a variant of PA; now classified separately as WHO Grade 2 in CNS5
More aggressive than classic PA, with higher recurrence rate and greater propensity for CSF dissemination
Typically arises in the hypothalamic/chiasmatic region in very young children (< 2 years)
Histology: prominent myxoid (mucin-rich) background, angiocentric arrangement of tumour cells, lacks Rosenthal fibres and eosinophilic granular bodies (which are hallmarks of classic PA)

7. Clinical Features

Cardinal presentations of brain tumours: ^[3]

High-grade diseases tend to present with subacute onset of signs/symptoms of raised ICP

Low-grade diseases tend to present with slowly progressive focal neurological signs/symptoms (negative symptoms) or epilepsy (positive symptoms)

PA, being low-grade, classically presents insidiously over weeks to months. However, because the cerebellum is the most common site and the posterior fossa is a tight space with the 4th ventricle immediately adjacent, raised ICP from obstructive hydrocephalus is actually a very common presenting feature even though the tumour itself is slow-growing.

7.2 Symptoms

Signs and symptoms of raised ICP: generalised, dull, constant headache (worse in morning), vomiting, decreased consciousness ^[3]

Symptom	Pathophysiological Basis
Headache — classically worse in the morning, exacerbated by coughing/straining/bending forward	Why worse in the morning? During sleep, the supine position impairs venous drainage from the brain (jugular veins have no valves and are dependent on gravity). Additionally, mild hypoventilation during sleep causes CO₂ retention → cerebral vasodilation → further increase in intracranial blood volume → ICP peaks in early morning. Coughing/Valsalva increases intrathoracic pressure → impedes venous return from the brain → transient ICP spike
Nausea and vomiting — may be "projectile" and can occur without nausea (especially in posterior fossa tumours)	Direct compression of the area postrema (chemoreceptor trigger zone) on the floor of the 4th ventricle by cerebellar PA, plus generalised raised ICP stimulating the vomiting centre in the medulla
Visual disturbance — blurred vision, transient visual obscurations, diplopia	Papilloedema (optic disc swelling from raised ICP transmitted along the optic nerve sheath), or 6th nerve palsy (false localizing sign — the abducens nerve has the longest intracranial course, most susceptible to stretch from diffuse raised ICP)
Lethargy / drowsiness / decreased consciousness	Raised ICP compromises cerebral perfusion (CPP = MAP − ICP); also direct brainstem compression from tonsillar herniation through foramen magnum
Irritability, personality change, declining school performance (in children)	Chronic raised ICP affecting frontal lobe function and global cerebral perfusion

High Yield – Infants vs. Older Children with Raised ICP

In infants with open fontanelles (< 18 months), raised ICP may present differently: the skull can expand, so the classic triad of headache/vomiting/papilloedema may be absent. Instead, look for: increasing head circumference (macrocephaly), bulging fontanelle, splayed sutures, sun-setting sign (eyes deviated downward from pressure on the tectal plate/Parinaud syndrome), failure to thrive, and irritability. The diagnosis may be delayed because vomiting is attributed to reflux and irritability to colic.

Symptom	Pathophysiological Basis
Unsteady gait / frequent falls	Vermian/midline involvement → truncal ataxia. The vermis coordinates axial musculature and posture.
Clumsiness, difficulty with fine motor tasks (handwriting deterioration, trouble with buttons)	Hemispheric involvement → appendicular ataxia on the ipsilateral side. The cerebellar hemisphere coordinates ipsilateral limb movements via the dentate nucleus → superior cerebellar peduncle → contralateral red nucleus/thalamus → motor cortex → (decussation at pyramids) → ipsilateral limb. Two decussations = net ipsilateral effect.
Slurred speech (dysarthria)	Cerebellar involvement → scanning/staccato speech from incoordination of speech musculature
Head tilt	Tonsillar herniation or trochlear nerve involvement; also a compensatory posture for diplopia or vestibular imbalance

Symptom	Pathophysiological Basis
Gradual visual loss — often unilateral initially; may be asymptomatic in young children (discovered on screening)	Direct compression of optic nerve fibres. In young children, visual loss may go unnoticed until very advanced; the child may present with strabismus or nystagmus instead
Squint / strabismus	Secondary to visual loss in one eye (sensory strabismus) or direct involvement of ocular motor pathways
Nystagmus (especially "see-saw" or monocular)	Involvement of optic chiasm or diencephalic structures affecting vestibulo-ocular pathways
Growth failure / short stature	Hypothalamic-pituitary axis disruption → GH deficiency
Precocious puberty	Mass effect stimulating hypothalamic GnRH release; or disruption of inhibitory pathways
Premature or delayed puberty (if involving hypothalamus) ^[4]
Diencephalic syndrome (infants): paradoxical emaciation, euphoria, hyperactivity, despite adequate caloric intake	Disruption of hypothalamic appetite/metabolic regulation centres; mechanism not fully understood but likely involves altered autonomic regulation and GH hypersecretion
Obesity (older children with hypothalamic PA)	Destruction of the ventromedial hypothalamic satiety centre → hyperphagia

Location	Symptoms	Pathophysiological Basis
Brainstem	Cranial nerve palsies (e.g., facial weakness, swallowing difficulty), long tract signs (hemiparesis, hyperreflexia)	Direct compression/infiltration of cranial nerve nuclei and corticospinal/corticobulbar tracts
Cerebral hemisphere	Seizures (most common presenting symptom for supratentorial PA), focal deficits depending on location	Cortical irritation → seizures; mass effect on eloquent cortex → motor/sensory/language deficits
Spinal cord	Back pain, progressive myelopathy (weakness, sensory level, bowel/bladder dysfunction)	Compression of spinal cord tracts and nerve roots

7.3 Signs

Sign	Pathophysiological Basis
Papilloedema ^[3]	Raised ICP is transmitted through the CSF in the subarachnoid space surrounding the optic nerve → compresses the central retinal vein → impaired venous drainage → optic disc swelling. Fundoscopy shows blurred disc margins, engorged veins, loss of venous pulsation, haemorrhages
6th nerve palsy (unilateral or bilateral)	False localizing sign — the abducens nerve (CN VI) has the longest intracranial subarachnoid course, running along the clivus and over the petrous temporal bone. Raised ICP or downward brain displacement stretches this nerve → lateral rectus palsy → convergent squint (inability to abduct the eye)
Cushing's triad (hypertension, bradycardia, irregular respiration) — late feature ^[3]	A pre-terminal sign. Brainstem compression from herniation → ischaemia of the medullary vasomotor centre → sympathetic surge → hypertension → baroreceptor-mediated reflex bradycardia. Irregular breathing reflects medullary respiratory centre dysfunction.
Altered consciousness (GCS decline)	Reticular activating system (RAS) compression from brainstem herniation
Bulging fontanelle, macrocephaly, split sutures (infants)	CSF accumulation → skull expansion before sutures fuse
Sun-setting sign (infants)	Upgaze palsy from pressure on the dorsal midbrain tectal plate (Parinaud syndrome) → eyes appear deviated downward with visible sclera above the iris
Brain herniation ^[3]	Uncal herniation: ipsilateral CN III palsy (dilated pupil, ptosis) + contralateral hemiparesis (compression of cerebral peduncle). Tonsillar herniation: respiratory arrest, death.

Sign	How to Elicit	Pathophysiological Basis
Truncal ataxia	Ask patient to sit upright unsupported; observe gait (broad-based, staggering)	Vermian lesion → impaired coordination of axial/truncal muscles
Appendicular ataxia	Finger-to-nose test, heel-to-shin test → past-pointing, dysmetria	Hemispheric lesion → impaired coordination of ipsilateral limb movements
Intention tremor	Finger-to-nose: tremor increases as finger approaches target	Disruption of cerebellar error-correction circuits (dentate nucleus outflow)
Dysdiadochokinesia	Rapid alternating movements (pronation/supination) → irregular rhythm	Impaired timing of sequential movements
Nystagmus (usually horizontal, towards the side of the lesion)	Gaze testing	Disruption of vestibulo-cerebellar connections (flocculonodular lobe)
Hypotonia (ipsilateral)	Reduced tone in limbs on side of lesion	Loss of cerebellar facilitation of gamma motor neuron tone
Pendular reflexes	Knee jerk → limb swings back and forth like a pendulum	Reduced damping of the stretch reflex arc by cerebellum
Scanning/staccato speech	Listen to speech	Incoordination of laryngeal and respiratory muscles

Mnemonic for cerebellar signs: "DANISH"

Dysdiadochokinesia / Dysmetria
Ataxia (truncal and appendicular)
Nystagmus
Intention tremor
Scanning speech / Slurred speech
Hypotonia

Sign	Pathophysiological Basis
Decreased visual acuity	Direct optic nerve/chiasm compression
Visual field defect — depending on location: monocular scotoma (nerve), bitemporal hemianopia (chiasm), homonymous hemianopia (tract)	Interruption of specific nerve fibre bundles at different points of the pathway
Relative afferent pupillary defect (RAPD / Marcus Gunn pupil) — tested with swinging flashlight test	Asymmetric optic nerve damage → reduced afferent input from affected eye → when light is swung to the affected eye, both pupils paradoxically dilate
Optic atrophy (pale disc on fundoscopy)	Chronic compression → Wallerian degeneration of optic nerve fibres
Proptosis (if intraorbital component)	Expanding mass within the orbit pushes the globe anteriorly
Strabismus	Sensory deprivation strabismus from poor vision in one eye

NF1 diagnostic features — "CAIN": Café-au-lait macules, Axillary freckling (Crowe sign), Iris hamartomas (Lisch nodules), Neurofibromas ^[4]

Sign	Detail
Café-au-lait macules ( ≥ 6, each > 5mm pre-pubertal or > 15mm post-pubertal)	Flat, uniformly hyperpigmented oval spots
Axillary/inguinal freckling (Crowe sign)	Multiple small freckles in skin fold areas
Lisch nodules (iris hamartomas)	Seen on slit-lamp examination; raised, tan-coloured; do not affect vision
Cutaneous neurofibromas	Soft, pedunculated skin-coloured nodules
Skeletal abnormalities — sphenoid wing dysplasia, tibial pseudoarthrosis, scoliosis

Sign	Basis
Short stature (height below 3rd centile, reduced growth velocity)	GH deficiency from hypothalamic-pituitary axis disruption
Tanner staging abnormalities — premature thelarche/adrenarche, or absent pubertal development	GnRH axis disruption
Wasting/cachexia (in diencephalic syndrome)	Metabolic derangement from hypothalamic destruction
Diabetes insipidus (polyuria, polydipsia — rare with PA, more common with craniopharyngioma or germinoma)	ADH-producing neuron destruction (less common with PA)

Understanding the histology helps solidify the concept:

Biphasic pattern: alternating compact (dense, piloid/hair-like) areas and loose (microcystic) areas
Rosenthal fibres: eosinophilic, corkscrew-shaped inclusions within astrocytic processes — highly characteristic of PA
Eosinophilic granular bodies (EGBs): another hallmark
Low mitotic activity (low Ki-67/MIB-1 index, typically < 2–4%)
Cyst with mural nodule pattern: the classic radiology appearance corresponds to a large cyst with a solid, enhancing nodular component on the wall
No significant nuclear atypia, necrosis, or microvascular proliferation (features that would suggest higher-grade glioma)
Despite the presence of vascular proliferation in some PAs, this does NOT indicate high grade (unlike in GBM) — this is a specific exception

Common Exam Pitfall

Vascular proliferation in a PA does NOT upgrade it to a higher grade. In GBM, microvascular proliferation and necrosis are defining features of Grade 4. However, in PA, florid endothelial proliferation can occur and is simply a feature of the tumour, not a sign of malignancy. Do not be misled by this on histopathology MCQs.

9. Neuroimaging Appearance (Brief Preview)

While detailed investigation will follow in the next section, a brief overview helps consolidate understanding:

Classic cerebellar PA: well-circumscribed, cystic lesion with a brightly enhancing mural nodule
- T1-weighted: hypointense cyst, iso/hypointense nodule
- T2-weighted: hyperintense cyst, hyperintense/mixed nodule
- Post-gadolinium: vivid enhancement of the mural nodule; cyst wall may or may not enhance
Optic pathway PA: fusiform enlargement of the optic nerve/chiasm, with variable enhancement
Minimal surrounding oedema (unlike high-grade gliomas which cause extensive vasogenic oedema)
No restricted diffusion on DWI (unlike medulloblastoma which shows restricted diffusion due to high cellularity)

Hypodense cystic lesion with isodense/slightly hyperdense enhancing nodule
May show hydrocephalus (dilated ventricles)
Calcification in ~10–20%

High Yield Summary

Pilocytic astrocytoma (PA) is the most common astrocytoma in children, classified as WHO Grade 1 — circumscribed, slow-growing, excellent prognosis.
Classical location is the cerebellum (60%), followed by the optic pathway/hypothalamus (25–30%). Can occur anywhere in the CNS.
Molecular hallmark: constitutive MAPK pathway activation — most commonly via BRAF-KIAA1549 fusion (70–80% of cerebellar PA). NF1-associated PA involves loss of neurofibromin (RAS-GAP).
NF1 association: ~50% of optic pathway gliomas occur in NF1 patients; the pathology is typically pilocytic astrocytoma. Screen NF1 children with annual ophthalmological assessment.
Rarely invasive, rarely undergoes malignant transformation — explained by oncogene-induced senescence (OIS).
Clinical presentation: (a) Raised ICP — headache (worse in morning), vomiting, papilloedema — from obstructive hydrocephalus (4th ventricle compression); (b) Cerebellar signs — ataxia (truncal > appendicular for vermian lesions), dysmetria, nystagmus, dysarthria; (c) Visual loss/field defects — for optic pathway PA; (d) Endocrine dysfunction — for hypothalamic PA.
Histological hallmarks: biphasic pattern (compact piloid + loose microcystic areas), Rosenthal fibres, eosinophilic granular bodies, low mitotic rate.
MRI appearance: well-circumscribed cystic lesion with brightly enhancing mural nodule. Minimal oedema. No restricted diffusion (helps distinguish from medulloblastoma).
WHO Astrocytoma Grading: Grade 1 (PA/SEGA) → Grade 2 (diffuse/pilomyxoid) → Grade 3 (anaplastic) → Grade 4 (GBM). Low-grade = Grade 1+2; High-grade = Grade 3+4.
Posterior fossa tumours in children (the "Big 3"): PA (most common), medulloblastoma, ependymoma. Location, age, and imaging features help differentiate.

Active Recall - Pilocytic Astrocytoma (Definition, Epidemiology, Etiology, Classification, Clinical Features)

Differential Diagnosis of Pilocytic Astrocytoma

The differential diagnosis of pilocytic astrocytoma (PA) depends entirely on where the tumour is located and how it presents. A child with a posterior fossa mass and raised ICP has a very different differential from a child with an optic pathway lesion causing gradual visual loss. The clinical approach is therefore to think: "What else could produce a mass in this location, in this age group, with these features?"

The three key clinical scenarios for which we build the differential are:

Posterior fossa (cerebellar) mass — the most common presentation
Optic pathway / hypothalamic mass — the second most common presentation
Supratentorial / other location mass — less common but still relevant

We also need to consider non-neoplastic mimics (abscess, demyelination, vascular malformations) that can look like a PA on imaging.

2. Clinical Approach to Differential Diagnosis — By Presentation Scenario

This is the bread-and-butter scenario. A child presents with raised ICP (headache worse in morning, vomiting, papilloedema) and/or cerebellar signs (ataxia, nystagmus, dysmetria).

In children: ~40% of brain tumours are infratentorial ^[3]. The "Big Three" posterior fossa tumours in paediatrics are pilocytic astrocytoma, medulloblastoma, and ependymoma.

High-grade diseases tend to present with subacute onset of signs/symptoms of raised ICP; low-grade diseases tend to present with slowly progressive focal neurological signs/symptoms or epilepsy ^[3]

The key differentials:

Tumour	WHO Grade	Peak Age	Typical Location	Growth	Key Distinguishing Features
Pilocytic astrocytoma	1	5–14 y	Cerebellar hemisphere	Slow, indolent	Cystic + mural nodule; no restricted diffusion on DWI; well-circumscribed; BRAF-KIAA1549 fusion
Medulloblastoma	4	5–7 y (median)	Midline cerebellar vermis exclusively	Rapid, aggressive	Male predominance; high propensity to disseminate through subarachnoid space (leptomeningeal dissemination); presents with signs and symptoms of increased ICP (extension into 4th ventricle causing obstructive hydrocephalus) and cerebellar signs ^[1]^[2]; solid, hyperdense, restricted diffusion on DWI
Ependymoma	2–3	2–6 y (younger than PA/medulloblastoma)	Floor of 4th ventricle ("plastic" — moulds through foramina of Luschka/Magendie)	Intermediate	Arises from ependymal lining; characteristic extension through 4th ventricle outlets; calcification common; heterogeneous enhancement
Atypical teratoid/rhabdoid tumour (AT/RT)	4	< 3 y (infants)	Posterior fossa (60%)	Very aggressive	Very young children; loss of INI1 (SMARCB1) on IHC is diagnostic; dismal prognosis
Brainstem glioma (diffuse intrinsic pontine glioma, DIPG)	4 (usually)	5–10 y	Pons (ventral, diffusely expanding)	Rapid	Cranial nerve palsies (especially CN VI, VII) + long tract signs + ataxia; diffuse pontine expansion on MRI; NOT biopsied traditionally (diagnosis on imaging); dismal prognosis
Haemangioblastoma	1	Young adults (20–40 y)	Cerebellar hemisphere	Slow	Cystic + mural nodule (can mimic PA); associated with von Hippel-Lindau (VHL) syndrome; prominent flow voids on MRI; often produces erythropoietin → polycythaemia

High Yield – The 'Big Three' Posterior Fossa Tumours of Childhood

Medulloblastoma is the MOST common type of malignant CNS tumour of childhood ^[1]^[2]. Together with PA and ependymoma, these three account for the vast majority of posterior fossa tumours in children. You must be able to distinguish them:

PA = cerebellar hemisphere, cystic + mural nodule, no restricted diffusion, slow-growing
Medulloblastoma = midline vermis, solid, restricted diffusion, rapid, leptomeningeal spread
Ependymoma = 4th ventricle floor, extends through foramina, "plastic tumour", calcification

Why does location help?

Medulloblastoma occurs exclusively in the cerebellum in midline cerebellar vermis ^[1]^[2] → a lateral cerebellar hemisphere lesion is much more likely PA
Ependymoma arises from ependymal cells lining the 4th ventricle → it grows from the ventricle floor and squeezes out through the foramina (like toothpaste from a tube), giving the characteristic "plastic" appearance
PA arises from cerebellar astrocytes, most often in the hemisphere → lateral, well-circumscribed, cystic

Why does DWI (diffusion-weighted imaging) help?

Medulloblastoma is a highly cellular "small round blue cell" tumour → tightly packed cells restrict the Brownian motion of water molecules → restricted diffusion (bright on DWI, dark on ADC map)
PA is cystic and loosely arranged → water moves freely → no restricted diffusion
This single MRI sequence can often distinguish the two most common posterior fossa tumours

A child (often < 6 years, especially if NF1) presents with gradual visual loss, proptosis, strabismus, or endocrine dysfunction.

A child presenting with a CN VI palsy should raise suspicion for raised ICP as a false localising sign — look for other signs of raised ICP including morning vomiting, cerebellar signs, and perform neuroimaging (usually MRI brain with contrast) to look for intracranial tumour ^[8]

Key differentials for an optic pathway/hypothalamic mass in a child:

Lesion	Key Features	How to Distinguish from PA
Pilocytic astrocytoma (optic pathway glioma)	Typically low-grade pilocytic astrocytoma; anywhere along optic nerve, chiasm, optic tract, optic radiation ^[4]; 50% associated with NF1 in this location	Fusiform enlargement of optic nerve/chiasm; T2-hyperintense; variable enhancement
Craniopharyngioma	Calcifications present in 50%; symptoms appearing in childhood in 50%; presents with hypopituitarism (growth retardation in child), diabetes insipidus (pituitary stalk compression), chiasmal compression (bitemporal hemianopia), obstruction of 3rd ventricle (hydrocephalus) ^[5]	Suprasellar, often both cystic and solid; calcification on CT is a major clue (PA rarely calcifies); arises from Rathke's pouch remnants; "machinery oil" cyst fluid
Hypothalamic hamartoma	Precocious puberty (isosexual), gelastic seizures (laughing seizures)	Non-enhancing, T1-isointense sessile mass at tuber cinereum; does NOT grow over time
Germinoma (CNS germ cell tumour)	Suprasellar > pineal; diabetes insipidus is a classic early feature; elevated β-hCG/AFP in serum/CSF	Homogeneously enhancing solid mass; strong restricted diffusion; responds dramatically to radiotherapy
Langerhans cell histiocytosis (LCH)	Hypothalamic-pituitary axis → diabetes insipidus; thickened pituitary stalk on MRI; bony lytic lesions elsewhere	Absent posterior pituitary bright spot on T1; multisystem disease (bone, skin, lung)
Pituitary adenoma	Mainly in adults; very rare in children ^[5]	Intrasellar (microadenoma < 10mm) or suprasellar extension (macroadenoma); hormone hypersecretion (prolactinoma most common)

Craniopharyngioma vs Optic Pathway PA — A Classic DDx

Both are suprasellar masses in children causing visual and endocrine dysfunction. The key differentiator is:

Craniopharyngioma: calcification in 50%, cystic with "machinery oil" fluid, arises from Rathke's pouch
PA (optic pathway): fusiform enlargement of the optic nerve/chiasm, rarely calcifies, associated with NF1

On CT, calcification in a suprasellar lesion in a child = think craniopharyngioma first. On MRI, fusiform optic nerve thickening in a child with café-au-lait spots = think PA/OPG in NF1.

In older children or young adults, PA can rarely occur in the cerebral hemispheres, presenting with seizures or focal neurological deficits.

Lesion	Key Features	How to Distinguish
Pilocytic astrocytoma	Well-circumscribed, enhancing, may be cystic	Uncommon in this location; molecular confirmation needed
Diffuse astrocytoma (WHO Grade 2)	Diffusely infiltrating, non-enhancing, T2/FLAIR hyperintense; IDH-mutant in most	Ill-defined borders (unlike PA's sharp margins); does NOT enhance (important clue)
Oligodendroglioma	Cortex-based, "gyriform" calcification on CT, IDH-mutant + 1p/19q co-deletion	Frontal lobe predilection; often presents with seizures; calcification pattern distinctive
Ganglioglioma / DNET	Temporal lobe; presents with drug-resistant epilepsy in young patients	"Bubbly" cortical mass; DNET has a specific multinodular appearance; both are surgically curable
Pleomorphic xanthoastrocytoma (PXA)	Temporal lobe, superficial cortex-based, cystic + mural nodule; can mimic PA	BRAF V600E mutation common; leptomeningeal involvement; more in adolescents/young adults
Brain abscess	Fever, ring-enhancing lesion, restricted diffusion in the cavity (pus restricts diffusion!)	History of sinusitis/otitis/immunocompromise/congenital heart disease (R→L shunt); DWI is key
Tumefactive demyelination	Acute/subacute; large, ring-enhancing white matter lesion; can mimic glioma	Open-ring enhancement (enhancement along the leading edge only); often responds to steroids

Mimic	Why It Can Mimic PA	How to Distinguish
Brain abscess	Ring-enhancing cystic lesion, especially in the cerebellum	Restricted diffusion within the cavity (pus is viscous → restricts water movement) — PA cyst contents do NOT restrict. Fever, raised inflammatory markers.
Haemangioblastoma	Cystic + mural nodule in the cerebellum — identical morphology to PA	Prominent flow voids (high vascularity); occurs in young adults rather than children; check for VHL features (retinal angiomas, renal cysts/RCC, phaeochromocytoma)
Arachnoid cyst	Posterior fossa cyst causing mass effect	CSF-signal on all MRI sequences; no enhancing solid component; displaces rather than invades
Epidermoid cyst	Posterior fossa; can mimic cystic lesion	Restricted diffusion (unlike PA cyst); "cauliflower" margins; off-midline CPA location
Vascular malformation (AVM, cavernoma)	Can present with seizures, headache	AVM: serpentine flow voids, no solid mass. Cavernoma: "popcorn" appearance with haemosiderin rim
Demyelination (ADEM, MS)	White matter lesion; ring enhancement possible	ADEM: multifocal, post-infectious, young child. MS: periventricular Dawson's fingers, older age group. Both usually respond to steroids.

The following mermaid diagram integrates the approach to differential diagnosis based on the age, location, and imaging features:

Feature	Pilocytic Astrocytoma	Medulloblastoma	Ependymoma	Craniopharyngioma	Haemangioblastoma
WHO Grade	1	4	2–3	1	1
Peak age	5–14 y	5–7 y ^[1]^[2]	2–6 y	Bimodal (child + 20–40 y)	20–40 y
Location	Cerebellar hemisphere	Midline vermis ^[1]^[2]	4th ventricle floor	Suprasellar	Cerebellar hemisphere
Morphology	Cystic + mural nodule	Solid, homogeneous	"Plastic" — extrudes through foramina	Cystic + solid + calcification 50% ^[5]	Cystic + mural nodule
Enhancement	Bright mural nodule	Homogeneous	Heterogeneous	Variable	Bright mural nodule
DWI	No restriction	Restricted (high cellularity)	Variable	No restriction	No restriction
CSF dissemination	Low metastatic potential; meningeal spread rare, mostly optic path region ^[1]^[2]	High propensity for leptomeningeal dissemination ^[1]^[2]	Can seed via CSF	No	No
Molecular	BRAF-KIAA1549 fusion	SHH, WNT, Grp3, Grp4 molecular subgroups	ZFTA fusion, YAP1 fusion	CTNNB1 (adamantinomatous), BRAF V600E (papillary)	VHL gene loss
Syndrome	NF1	Turcot syndrome (FAP + brain tumours) ^[6]	NF2	None	VHL
Prognosis	Excellent ( > 95% 10y OS)	Variable (50–80% 5y OS depending on subgroup)	Intermediate	Good if complete resection, but high recurrence	Excellent if resectable

Turcot syndrome = familial colon cancer + brain tumours ^[6] — in the context of FAP, brain tumours include medulloblastoma, ependymomas, high-grade astrocytomas ^[6]. The medulloblastoma in Turcot/FAP is driven by APC/WNT pathway mutations, corresponding to the WNT molecular subgroup (best prognosis among medulloblastoma subgroups).

5. How to Narrow the DDx — "Red Flags" and Pattern Recognition

Well-circumscribed cystic lesion with enhancing mural nodule
Lateral cerebellar hemisphere location
Slow, insidious clinical course (weeks to months)
No restricted diffusion on DWI
Minimal surrounding vasogenic oedema
NF1 features present → optic pathway PA until proven otherwise

Red Flag	What It Suggests Instead
Midline vermis solid mass with restricted diffusion	Medulloblastoma
Very young child ( < 3y) with aggressive posterior fossa tumour	AT/RT
Calcification in a suprasellar lesion	Craniopharyngioma (calcification in 50%) ^[5]
Diabetes insipidus as a presenting feature	Craniopharyngioma, germinoma, LCH — DI from pituitary stalk compression ^[5]; DI is uncommon in PA
Diffuse pontine expansion with CN palsies	DIPG (diffuse midline glioma, H3K27-altered)
Multiple enhancing lesions at grey-white junction in adult with known cancer	Brain metastases ^[3]^[7]
Restricted diffusion within a cystic cavity + fever	Brain abscess
Flow voids within a mural nodule in a young adult	Haemangioblastoma (VHL)
Bilateral acoustic masses	NF2 (vestibular schwannoma) — not PA
Leptomeningeal spread at diagnosis	Medulloblastoma (high propensity to disseminate through subarachnoid space) ^[1]^[2]; or pilomyxoid astrocytoma variant

When a child with NF1 has a brain lesion:

NF-associated bright spots (focal areas of signal intensity / unidentified bright objects, UBO) ^[4]^[9]: T2-hyperintense spots in basal ganglia, cerebellum, brainstem — these are NOT tumours and are NOT associated with focal neurological deficits; they resolve over time ( < 30 years). Do not confuse with PA on MRI.
An optic pathway mass in NF1 is typically low-grade pilocytic astrocytoma ^[4] — but biopsy confirmation is not always required if imaging is classic and the child has NF1
Megalencephaly ^[9] and cerebrovascular dysplasia (e.g., Moyamoya) ^[9] may also be seen in NF1 and should not be confused with tumour

MRI appearance of common tumours: ^[10]

High-grade glioma: decreased T1W, heterogeneous enhancement with surrounding vasogenic oedema (increased T2W) ± central necrosis

Low-grade glioma: increased T2W, non-enhancing expansile lesion without surrounding vasogenic oedema

Primary CNS lymphoma: solitary/multifocal T2W iso/hypointense, contrast-enhancing lesions in subcortical regions, classically associated with prominent diffusion restriction on DWI

Brain metastases: round, well-circumscribed contrast-enhancing lesion with variable signal on T1/2W images ± surrounding oedema (if large), involve multiple regions especially if multiple intracranial compartments

Meningioma: extra-axial, dura-based T1W hypo/isointense, T2W iso/hyperintense lesion with strong homogeneous enhancement

PA on MRI: well-circumscribed, cystic with enhancing mural nodule, T2-hyperintense, minimal oedema, no restricted diffusion — this pattern is consistent with the low-grade glioma description above but with the additional distinctive cystic-nodular architecture.

Exam Pearl — Imaging DDx Quick Hits

Cystic + mural nodule in child's cerebellum → PA (if no flow voids) vs haemangioblastoma (if flow voids, young adult, VHL)
Solid midline cerebellar mass with restricted diffusion → Medulloblastoma
Mass from 4th ventricle floor extending through foramina → Ependymoma ("plastic tumour")
Suprasellar mass with calcification → Craniopharyngioma
Diffuse pontine expansion → DIPG
Ring-enhancing lesion with restricted diffusion in cavity → Abscess (not tumour)
Extra-axial, dura-based, homogeneously enhancing → Meningioma

Because brain tumour type is strongly age-dependent, organizing the DDx by age is clinically powerful:

Age Group	Most Likely Posterior Fossa Tumour	Most Likely Suprasellar Tumour	Key Points
Infant ( < 2y)	AT/RT, choroid plexus papilloma	PA (diencephalic syndrome), craniopharyngioma	AT/RT: INI1 loss; CPP: hydrocephalus from CSF overproduction
Young child (2–6y)	Medulloblastoma, ependymoma, PA	Craniopharyngioma, optic pathway PA (especially if NF1)	Ependymoma peaks youngest; medulloblastoma peaks 5–7y
Older child / adolescent (7–18y)	PA (most common benign), medulloblastoma (most common malignant)	Craniopharyngioma, germinoma	Germinoma: check β-hCG, AFP; diabetes insipidus
Young adult (18–40y)	Haemangioblastoma, metastasis	Pituitary adenoma, craniopharyngioma	Haemangioblastoma can perfectly mimic PA on imaging
Older adult ( > 40y)	Metastasis, haemangioblastoma	Pituitary adenoma, meningioma	PA is rare in this age group

High Yield Summary — Differential Diagnosis of Pilocytic Astrocytoma

The DDx depends on location: posterior fossa → medulloblastoma, ependymoma, AT/RT, haemangioblastoma, DIPG; optic pathway/suprasellar → craniopharyngioma, germinoma, LCH, hypothalamic hamartoma; supratentorial → diffuse astrocytoma, oligodendroglioma, ganglioglioma, PXA.
"Big Three" paediatric posterior fossa tumours: PA (lateral hemisphere, cystic + mural nodule, no restricted diffusion), medulloblastoma (midline vermis, solid, restricted diffusion, leptomeningeal spread), ependymoma (4th ventricle floor, "plastic", extends through foramina).
Calcification on CT in a suprasellar mass = craniopharyngioma until proven otherwise.
DWI is the single most useful MRI sequence for posterior fossa DDx: restricted diffusion → medulloblastoma or abscess; no restriction → PA.
NF1 UBOs (unidentified bright objects) are T2-hyperintense foci that are NOT tumours and must not be confused with PA.
Haemangioblastoma mimics cerebellar PA perfectly (cystic + mural nodule) but occurs in young adults, has flow voids, and is associated with VHL syndrome.
Turcot syndrome (FAP variant) is associated with medulloblastoma (WNT subgroup).
Brain abscess mimics ring-enhancing tumour but has restricted diffusion within the cystic cavity (pus restricts water movement).

Active Recall - Differential Diagnosis of Pilocytic Astrocytoma

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, p.1258–1260 (Features of different brain tumours — Astrocytomas, PNETs/Medulloblastoma) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, p.530 (Features of different brain tumours — Astrocytomas, PNETs/Medulloblastoma) ^[3] Senior notes: Ryan Ho Neurology.pdf, p.161–165 (Intracranial Tumours — General Principles, Clinical Approach, Brain Metastasis, Gliomas) ^[4] Senior notes: Ryan Ho Rheumatology.pdf, p.171–172 (Neurofibromatosis type 1 — Optic pathway glioma, Diagnostic criteria, Neuroimaging findings) ^[5] Senior notes: Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf, p.6 (Craniopharyngiomas — calcification, presentation) ^[6] Senior notes: Ryan Ho GI.pdf, p.181 (Familial adenomatous polyposis — Turcot syndrome, brain tumours including medulloblastoma) ^[7] Senior notes: Ryan Ho Neurology.pdf, p.164 (Brain Metastasis — epidemiology, imaging features) ^[8] AOS material: AOS - Ophthalmology (Ans:Notes).pdf, p.3 (Neuro-ophthalmology — CN VI palsy in child as false localising sign of raised ICP) ^[9] Senior notes: Adrian Lui Pediatrics Notes.pdf, p.148 (NF1 — UBOs/FASI, megalencephaly, cerebrovascular dysplasia) ^[10] Senior notes: Adrian Lui Pediatrics Notes.pdf, p.431 (MRI appearance of common tumours — high-grade glioma, low-grade glioma, CNS lymphoma, brain metastases, meningioma)

Diagnostic Criteria, Algorithm, and Investigations for Pilocytic Astrocytoma

1. Diagnostic Criteria — Conceptual Framework

There is no single set of formal "diagnostic criteria" for pilocytic astrocytoma analogous to, say, the Jones criteria for rheumatic fever. Instead, the diagnosis is made through the integration of three pillars:

Clinical presentation — age-appropriate symptoms and signs (raised ICP, cerebellar syndrome, visual loss, endocrine dysfunction)
Neuroimaging — characteristic MRI features (the most important pre-operative tool)
Histopathological and molecular confirmation — definitive diagnosis (gold standard)

However, there is an important exception: in the context of NF1-associated optic pathway glioma, the diagnosis can be made on clinical and radiological grounds alone without biopsy, because the imaging appearance in a child with established NF1 is sufficiently characteristic and biopsy carries risk to the visual apparatus.

The 2021 WHO Classification of CNS Tumours ("CNS5") mandates an integrated diagnosis combining histological features with molecular markers. For PA specifically:

Domain	Required Features
Histology	Biphasic pattern (compact piloid areas + loose microcystic areas); Rosenthal fibres; eosinophilic granular bodies (EGBs); low mitotic activity (Ki-67 typically < 2–4%); no significant necrosis or brisk mitotic activity
Molecular	MAPK pathway alteration — most commonly BRAF-KIAA1549 fusion (especially cerebellar) or BRAF V600E, NF1 loss, FGFR1 alteration, or NTRK fusion
Grading	WHO CNS Grade 1
Tumour category	Circumscribed astrocytic glioma (distinct from diffuse astrocytic gliomas)
Key exclusions	Must NOT have IDH mutation (which would make it a diffuse astrocytoma), H3K27 alteration (which would make it a diffuse midline glioma), or CDKN2A homozygous deletion (which suggests higher-grade transformation)

High Yield — Integrated Diagnosis in CNS5

The modern WHO approach requires both histology AND molecular profiling for a complete diagnosis. A tumour that looks like PA under the microscope but has IDH mutation is reclassified as a diffuse astrocytoma — the molecular trumps morphology. Similarly, a midline tumour that looks pilocytic but harbours H3K27M mutation is a diffuse midline glioma (WHO Grade 4) with a dismal prognosis. Always check molecular markers.

When PA manifests as an optic pathway glioma, you must consider whether the child has NF1. The NF1 diagnostic criteria are clinically important:

Diagnostic criteria for NF1: ≥ 2 out of 7 (CAFESPOT) ^[4]^[9]

Café-au-lait macules (≥ 6, > 5mm prepubertal; > 15mm post-pubertal)

Axillary / Inguinal freckling

NeuroFibromas (≥ 2 of any types or 1 plexiform)

Eye hamartoma (≥ 2 Lisch nodules)

Skeletal lesion: sphenoid dysplasia, long bone cortical thickening ± pseudoarthrosis

Positive FHx (1st degree relative)

Optic Tumours

Why does this matter? If a child already meets NF1 criteria and has a fusiform enlargement of the optic nerve on MRI, the diagnosis of optic pathway pilocytic astrocytoma is made clinically + radiologically without the need for biopsy. Conversely, discovery of an optic pathway glioma may itself be the criterion that clinches the NF1 diagnosis (it counts as one of the "CAFESPOT" features).

The 2021 revised NF1 diagnostic criteria (Legius et al., 2021) also now include pathogenic NF1 variant on genetic testing as a standalone criterion. If genetic confirmation of NF1 is available, only one additional clinical criterion is needed.

The following algorithm outlines the step-by-step clinical approach from initial suspicion to definitive diagnosis:

Key decision points explained:

CT first if acute raised ICP — CT is fast (1 minute), widely available, and excellent for detecting hydrocephalus and haemorrhage. It serves as a triage tool. CT examination time is 1 minute vs MRI 20 minutes ^[11]. However, CT alone cannot definitively characterize the tumour.
MRI with contrast is always required — MRI with contrast is generally preferred over CT ^[3] because it provides better soft tissue delineation, especially useful at skull base, craniocervical junction, brainstem ^[3]. MRI is the definitive imaging modality for tumour characterization.
NF1 optic pathway glioma = no biopsy — the imaging pattern is diagnostic in the appropriate clinical context. Biopsy risks damaging the optic nerve.
Surgery is both diagnostic and therapeutic for resectable PA — when gross total resection (GTR) is feasible, the surgically removed specimen provides tissue for histology and molecular profiling.
Stereotactic biopsy — reserved for surgically inaccessible tumours (deep locations, brainstem) where tissue diagnosis is needed to guide management.

3. Investigation Modalities — Detailed Breakdown

3.1 Neuroimaging

Role: Initial triage, detection of hydrocephalus, emergency assessment.

CT brain ± contrast: ^[3]

Site and multiplicity

Mass effect

Contrast enhancement — normal brain tissue does not enhance (due to BBB); enhancement indicates: (1) outside BBB (e.g., meningioma — homogeneously enhancing); (2) disruption of BBB (e.g., high-grade tumours, stroke, inflammation) ^[3]

CT Feature	Pilocytic Astrocytoma Finding	Interpretation / Why
Density	Hypodense cystic component; iso/slightly hyperdense mural nodule	Cyst fluid is similar to CSF (low protein); solid tumour component is near brain density
Calcification	Uncommon (~10–20%)	Helps distinguish from craniopharyngioma (50% calcified) and oligodendroglioma (often calcified)
Contrast enhancement	Vivid enhancement of the mural nodule	PA disrupts the BBB locally at the solid nodular component → contrast leaks through; the cyst wall may or may not enhance
Hydrocephalus	Dilated lateral and 3rd ventricles (if posterior fossa location)	Obstructive hydrocephalus from 4th ventricle compression — look for temporal horn dilatation (earliest sign of hydrocephalus on CT)
Mass effect	Compression of 4th ventricle, effacement of posterior fossa cisterns	Posterior fossa is a confined space; even a relatively small mass can cause significant mass effect

Note characteristics of lesions on CT: ^[11]

Location/distribution, number, size, shape, outline/contour (well-defined vs ill-defined), attenuation or density, contrast enhancement pattern

Evaluate effect on adjacent structures

Shape significance: PA typically has a round/oval shape → slow, displacing growth pattern ^[11], consistent with a benign, well-circumscribed tumour. An irregular or infiltrative shape would suggest malignancy ^[11] and point away from PA.

Role: Definitive tumour characterization, surgical planning, assessment of CSF dissemination.

MRI with contrast is generally preferred over CT ^[3] for brain tumours. It provides better soft tissue delineation, especially useful at skull base, craniocervical junction, brainstem ^[3].

MRI Sequence	PA Findings	Interpretation / Why
T1-weighted	Hypointense cyst; iso/hypointense mural nodule	T1 reflects tissue composition: water (cyst) = dark; solid tissue = intermediate. Protein-rich cyst contents may show slightly higher signal than CSF.
T2-weighted / FLAIR	Hyperintense cyst; hyperintense/mixed mural nodule	T2 reflects water content: more water = brighter. Cyst fluid is very bright. FLAIR suppresses free water signal — if the cyst suppresses on FLAIR, contents are CSF-like; if it stays bright, contents are proteinaceous.
Post-gadolinium T1	Vivid, homogeneous enhancement of the mural nodule; cyst wall may or may not enhance	Gadolinium is an extracellular contrast agent that leaks through disrupted BBB → tumour tissue enhances. The mural nodule is the "living" tumour; the cyst wall may be reactive gliosis or tumour-lined (if it enhances, the surgeon must resect it too).
DWI / ADC	No restricted diffusion (mural nodule and cyst both show no restriction)	Low cellularity → water molecules move freely → no restriction. This is the key feature distinguishing PA from medulloblastoma (which restricts). Also distinguishes from brain abscess (pus restricts).
MR spectroscopy	Elevated choline (cell membrane turnover), reduced NAA (neuronal loss), +/- lactate peak	Choline:NAA ratio increased but less dramatically than high-grade gliomas. Choline:creatine ratio elevated. Lactate may be present in cystic component. These findings are non-specific but can support neoplastic diagnosis.
Perfusion MRI (DSC/DCE)	Low relative cerebral blood volume (rCBV) compared to high-grade gliomas	PA is low-grade → less neoangiogenesis → lower perfusion. However, some PAs can show elevated perfusion at the mural nodule (due to their characteristic vascular proliferation — which does NOT indicate malignancy in PA, as discussed previously).
MR tractography / DTI	Displacement of white matter tracts rather than infiltration	Functional MRI (fMRI): identify important cortical areas to guide surgical resection; MRI diffusion tensor imaging (DTI, tractography): identify important tracts to guide surgical resection ^[10]. PA displaces tracts because it is circumscribed (unlike diffuse gliomas which infiltrate along tracts).

PA by location — specific MRI patterns:

Location	Classic MRI Pattern
Cerebellum	"Cyst with enhancing mural nodule" — the most recognized PA pattern. Large cyst (often > 3 cm) with a smaller vivid nodule. Minimal perilesional oedema.
Optic pathway	Fusiform enlargement of the optic nerve ± chiasm. T2-hyperintense. Enhancement variable (may be none, patchy, or homogeneous). In NF1, may extend posteriorly along the optic tracts.
Hypothalamus	Large, often solid or mixed cystic-solid mass in the suprasellar/hypothalamic region. Can be difficult to distinguish from craniopharyngioma without calcification assessment.
Brainstem	Well-circumscribed, dorsally exophytic mass (often from the dorsal midbrain/tectal plate or cervicomedullary junction). Enhances with contrast. Important to distinguish from DIPG (diffuse expansion of the pons).
Spinal cord	Intramedullary, well-circumscribed, T2-bright, enhancing mass with possible associated syrinx.

High Yield — Cyst Wall Enhancement and Surgical Implications

On post-gadolinium MRI, if the cyst wall enhances, it may contain tumour cells → the surgeon should attempt to resect both the nodule AND the enhancing cyst wall for complete removal. If the cyst wall does not enhance, it likely represents compressed/reactive brain parenchyma and does not need resection. This MRI detail directly impacts surgical planning and recurrence risk.

Feature	CT	MRI
Speed	1 min ^[11]	20 min ^[11]
Radiation	Yes ^[11]	No ^[11]
Availability	Good ^[11]	Fair ^[11]
Soft tissue resolution	Moderate	Superior — allows better soft tissue delineation ^[3]
Posterior fossa assessment	Poor (bone artefact from petrous bones)	Excellent
Detection of calcification	Excellent	Poor (calcification may be invisible on MRI)
Detection of haemorrhage	Good acutely	Good (SWI/GRE sequences)
Tumour characterization	Limited	Excellent (multiple sequences, DWI, spectroscopy, perfusion)
Hydrocephalus	Good	Good
Use in emergencies	First-line (fast, available)	Second-line (slower, may need sedation in children)

Why is CT poor for posterior fossa tumours? The petrous temporal bones create beam-hardening artefact on CT that degrades image quality in the posterior fossa. MRI does not use X-rays and therefore has no bone artefact — it provides exquisite posterior fossa detail.

Role: Staging — to assess for leptomeningeal / "drop" metastasis.

While PA has low metastatic potential ^[1]^[2], craniospinal MRI is obtained:
- Pre-operatively in the posterior fossa (to establish baseline before surgical manipulation which can cause artefactual enhancement along meninges)
- In cases where there is concern for CSF dissemination (e.g., pilomyxoid variant, optic pathway PA with extension)
- Standard practice in many paediatric neuro-oncology protocols
Findings if positive: enhancing nodules along the spinal cord surface, nerve roots (sugar-coating appearance), or within the ventricles

Laboratory tests are not diagnostic for PA but are important for:

Investigation	Purpose	Expected Findings
CBP (complete blood picture)	Baseline before surgery/chemotherapy	Usually normal
Coagulation profile (PT, APTT, INR)	Pre-operative assessment	Usually normal
Renal function tests (RFT), electrolytes	Baseline; detect SIADH or diabetes insipidus (hypothalamic PA)	Hyponatraemia (SIADH) or hypernatraemia with dilute urine (DI)
Liver function tests (LFT)	Baseline before chemotherapy	Usually normal
Endocrine panel (if hypothalamic/suprasellar PA)	Assess hypothalamic-pituitary axis function	Growth hormone, IGF-1, cortisol (8am), thyroid function (TSH/fT4), prolactin, LH/FSH, testosterone/oestradiol — may show single or multiple anterior pituitary hormone deficiencies
Serum tumour markers — β-hCG, AFP	To exclude CNS germ cell tumour (important DDx in suprasellar region)	Should be negative in PA. If elevated → think germinoma (β-hCG) or yolk sac tumour (AFP)
CSF cytology (via LP — only if safe, i.e., no risk of herniation)	Staging — detect malignant cells in CSF	Usually negative in PA; positive → suggests either higher-grade tumour or rare PA with leptomeningeal spread
CSF tumour markers (β-hCG, AFP)	DDx — germ cell tumour	Should be negative in PA

Important Safety Note

Lumbar puncture is CONTRAINDICATED if there is raised ICP with risk of herniation. In a child with a posterior fossa mass and hydrocephalus, LP can cause tonsillar herniation (brainstem compression → respiratory arrest → death). CSF should be obtained intra-operatively during surgery or after CSF diversion (EVD/VP shunt) if needed.

Essential for all suspected PA, especially optic pathway lesions:

Test	Purpose	Findings in PA
Visual acuity (Snellen/LogMAR or age-appropriate method)	Quantify visual loss	Decreased in optic pathway PA
Visual field testing (Goldmann or Humphrey perimetry; confrontation in young children)	Map field defects	Bitemporal hemianopia (chiasm), monocular field cut (nerve), homonymous hemianopia (tract)
Colour vision (Ishihara plates)	Detect optic nerve dysfunction (colour affected early)	Reduced colour discrimination (dyschromatopsia)
Pupillary examination — swinging flashlight test	Detect RAPD	Present if asymmetric optic nerve involvement
Fundoscopy	Assess for papilloedema (raised ICP) or optic atrophy (chronic compression)	Papilloedema (swollen disc margins, haemorrhages, engorged veins) or optic atrophy (pale disc)
Slit-lamp examination	Lisch nodules (NF1)	Raised, tan-coloured iris hamartomas — present in adult NF1 patients, support NF1 diagnosis
OCT (optical coherence tomography)	Quantify retinal nerve fibre layer (RNFL) thickness	Thinning indicates chronic optic nerve damage; useful for longitudinal monitoring

3.4 Histopathology and Molecular Pathology (Gold Standard)

Tissue is obtained via surgical resection (preferred — both diagnostic and therapeutic) or stereotactic biopsy (when resection is not feasible).

Feature	Description	Significance
Biphasic pattern	Alternating compact (piloid, densely fibrillar) and loose (microcystic, spongy) areas	Pathognomonic of PA; not seen in diffuse astrocytomas
Rosenthal fibres	Eosinophilic, corkscrew-shaped intracytoplasmic inclusions	Highly characteristic of PA (also seen in chronic reactive gliosis but context matters)
Eosinophilic granular bodies (EGBs)	Refractile, PAS-positive cytoplasmic droplets	Common in PA and other low-grade circumscribed gliomas
Low mitotic index	Few mitoses; Ki-67/MIB-1 index typically < 2–4%	Confirms low-grade (Grade 1) designation
Vascular proliferation (may be present)	Endothelial hyperplasia, glomeruloid vessels	In PA, this does NOT indicate high grade (unlike GBM). A known PA-specific exception.
No necrosis	Absence of pseudopalisading necrosis	Necrosis would suggest higher-grade glioma (Grade 4)
GFAP positivity (immunohistochemistry)	Tumour cells express glial fibrillary acidic protein	Confirms astrocytic lineage
Olig2 positivity	Nuclear transcription factor positive in gliomas	Supports glial origin

Molecular Marker	Method	Expected Finding in PA	Clinical Relevance
BRAF-KIAA1549 fusion	FISH, RT-PCR, next-generation sequencing (NGS), or methylation profiling	Present in ~70–80% of cerebellar PA	Near-pathognomonic for PA; also a therapeutic target (MEK inhibitors)
BRAF V600E mutation	Immunohistochemistry (VE1 antibody), PCR, NGS	Present in ~5–10% of PA (more common in supratentorial PA)	Targetable with BRAF inhibitors (dabrafenib); also found in PXA, ganglioglioma
NF1 gene status	Clinical assessment (NF1 criteria) ± germline genetic testing	NF1 loss in NF1-associated PA	Confirms NF1-associated tumourigenesis; impacts surveillance strategy
IDH-1/2 mutation	Immunohistochemistry (R132H antibody for IDH1), sequencing	NEGATIVE (wild-type)	PA must be IDH-wildtype. IDH mutation → reclassify as diffuse astrocytoma
H3K27M mutation	Immunohistochemistry, sequencing	NEGATIVE	If positive → diffuse midline glioma (WHO Grade 4), even if histology looks pilocytic
CDKN2A/B homozygous deletion	FISH, methylation array	Usually absent	If present, suggests risk of higher-grade transformation; associated with worse prognosis
1p/19q co-deletion	FISH, molecular testing	ABSENT	If present → oligodendroglioma (different tumour category entirely)
ATRX	Immunohistochemistry	Retained (normal nuclear expression)	Loss of ATRX → diffuse astrocytoma. Retained in PA.
DNA methylation profiling	Methylation array (e.g., Heidelberg classifier)	Matches PA methylation class	Increasingly used as the definitive molecular classifier; can resolve ambiguous cases

High Yield — Molecular Red Flags That Change the Diagnosis

If you see ANY of the following in what looks histologically like a "pilocytic astrocytoma", the diagnosis CHANGES:

IDH mutation present → Reclassify as diffuse astrocytoma, IDH-mutant (WHO Grade 2–4)
H3K27M mutation present → Reclassify as diffuse midline glioma, H3K27-altered (WHO Grade 4) — even if in the cerebellum or brainstem, this carries a dismal prognosis
1p/19q co-deletion → Reclassify as oligodendroglioma (WHO Grade 2–3)
CDKN2A homozygous deletion → Suggests higher-grade behaviour regardless of histological appearance

Molecular profiling is not optional — it is mandatory for accurate diagnosis under WHO CNS5.

Investigation	Purpose	Details
Functional MRI (fMRI)	Identify important cortical areas to guide surgical resection ^[10]	Maps eloquent cortex (motor, language, visual areas) by detecting BOLD signal changes during task performance. Important when PA abuts eloquent regions.
MRI diffusion tensor imaging (DTI / tractography)	Identify important tracts to guide surgical resection ^[10]	Visualises white matter tracts (corticospinal tract, optic radiations, arcuate fasciculus). PA displaces rather than infiltrates tracts — tractography confirms safe surgical corridors.
Cerebral angiography (CTA/MRA/DSA)	Assess vascular anatomy in complex cases	Rarely needed; may be helpful if haemangioblastoma is in the differential (prominent feeding arteries and draining veins).
EEG	If seizures are a presenting feature (supratentorial PA)	Localise seizure focus; guide anti-epileptic drug management
Audiometry	Baseline hearing assessment pre-surgery (especially for CPA or brainstem lesions near CN VIII)	Document pre-operative hearing status
Growth chart review / bone age	If hypothalamic PA with growth failure	Delayed bone age suggests GH deficiency; essential for endocrine follow-up

PA staging is much simpler than for medulloblastoma or ependymoma, reflecting its benign biology. However, baseline evaluation should include:

Investigation	When	Purpose
MRI whole neuro-axis (craniospinal)	Pre-operatively or within 72 hours post-operatively	Detect drop metastases (rare but important); post-operative MRI done within 48–72 hours to assess extent of resection before post-surgical enhancement obscures the picture
CSF cytology	If LP is safe (post-EVD or intra-operatively)	Detect malignant cells in CSF
Post-operative MRI brain with contrast	Within 24–72 hours post-resection	Assess extent of resection — gross total resection (GTR) vs subtotal resection (STR). Residual enhancing tumour = STR → informs need for adjuvant therapy or surveillance

Finding	Supports PA Diagnosis	Against PA Diagnosis
Child 5–14 years with cerebellar mass	✅ Most common age and location
Cystic + enhancing mural nodule on MRI	✅ Classic PA pattern
No restricted diffusion on DWI	✅ Low cellularity	❌ Restricted diffusion → medulloblastoma/abscess
Minimal perilesional oedema	✅ Low-grade, circumscribed	❌ Extensive oedema → high-grade glioma or metastasis
NF1 features + fusiform optic nerve thickening	✅ NF1-associated OPG (PA)
Calcification on CT	⚠️ Possible but uncommon (~10–20%)	❌ Prominent calcification → craniopharyngioma, oligodendroglioma
BRAF-KIAA1549 fusion on molecular testing	✅ Near-pathognomonic for PA
IDH mutation positive		❌ Not PA → diffuse astrocytoma
H3K27M mutation positive		❌ Not PA → diffuse midline glioma (Grade 4)
Biphasic pattern + Rosenthal fibres on histology	✅ Hallmark features
High Ki-67 ( > 10%), necrosis, brisk mitoses		❌ Suggests higher-grade tumour

High Yield Summary — Diagnosis of Pilocytic Astrocytoma

Diagnosis requires integration of imaging + histopathology + molecular profiling (WHO CNS5 integrated diagnosis). There are no standalone "diagnostic criteria" like rheumatic fever.
MRI brain with gadolinium is the gold standard imaging modality — look for cystic + enhancing mural nodule (cerebellar PA) or fusiform optic nerve thickening (OPG).
DWI is the key differentiating MRI sequence: no restricted diffusion in PA vs restricted diffusion in medulloblastoma and abscess.
CT is for triage — fast, detects hydrocephalus and calcification, but inferior to MRI for tumour characterization.
Normal brain tissue does not enhance on contrast CT/MRI because of the intact BBB; enhancement implies BBB disruption (tumour, inflammation) or structures outside the BBB (meninges).
NF1-associated OPG does not require biopsy — diagnosis is clinical + radiological in a child meeting NF1 criteria (CAFESPOT: ≥ 2 of 7).
Molecular markers that MUST be negative in PA: IDH mutation, H3K27M mutation, 1p/19q co-deletion, CDKN2A homozygous deletion. If any are present → reclassify.
BRAF-KIAA1549 fusion (~70–80% of cerebellar PA) is near-pathognomonic and therapeutically actionable (MEK/BRAF inhibitors).
Post-operative MRI within 24–72 hours is essential to assess extent of resection (GTR vs STR) before post-surgical changes obscure the field.
LP is contraindicated if raised ICP with risk of herniation — obtain CSF intra-operatively or after CSF diversion.

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for Pilocytic Astrocytoma

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, p.1258–1260 (Features of different brain tumours — Astrocytomas) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, p.530 (Features of different brain tumours — Astrocytomas) ^[3] Senior notes: Ryan Ho Neurology.pdf, p.162–165 (Intracranial Tumours — Investigations, CT brain, MRI, Gliomas) ^[4] Senior notes: Ryan Ho Rheumatology.pdf, p.171–172 (NF1 — Diagnostic criteria, Optic pathway glioma, Neuroimaging) ^[9] Senior notes: Adrian Lui Pediatrics Notes.pdf, p.148 (NF1 — Diagnostic criteria CAFESPOT, Neuroimaging findings) ^[10] Senior notes: Adrian Lui Pediatrics Notes.pdf, p.431 (Gliomas — Classification, MRI appearance, fMRI, DTI) ^[11] Senior notes: Ryan Ho Diagnostic Radiology.pdf, p.39–50 (CT interpretation, CT vs MRI comparison)

Management of Pilocytic Astrocytoma

Management of pilocytic astrocytoma (PA) is guided by four fundamental principles:

Surgery is the cornerstone — gross total resection (GTR) is curative in the majority of cases
Location determines resectability — cerebellar PA is usually resectable; optic pathway/hypothalamic PA often is not
Adjuvant therapy is reserved for progressive/unresectable disease — most PA patients never need chemotherapy or radiotherapy
Multidisciplinary team (MDT) approach — neurosurgeon, paediatric oncologist, radiation oncologist, neuro-ophthalmologist, endocrinologist, neuropsychologist, rehabilitation team

Watchful waiting may be adopted in low-grade astrocytomas ^[3] Surgical: maximal safe removal as 1st line in all operable gliomas ^[3]

These two statements from the senior notes capture the two ends of the PA management spectrum: observation when safe, surgery when indicated, always prioritising functional preservation.

3. Treatment Modalities — Detailed Breakdown

Why this comes first: A child with a posterior fossa PA causing obstructive hydrocephalus can present acutely with life-threatening raised ICP. This must be addressed before any definitive tumour surgery.

Intervention	Mechanism	Details
External ventricular drain (EVD)	A catheter is placed into the lateral ventricle through a frontal burr hole → drains CSF externally → reduces ICP immediately	Temporary measure; allows control of ICP while the patient is stabilised and definitive surgery is planned. ICP monitoring via intraventricular catheter / external ventricular drainage by burr hole ^[12]
Endoscopic third ventriculostomy (ETV)	A fenestration is created in the floor of the 3rd ventricle → CSF bypasses the obstructed aqueduct/4th ventricle → drains directly into the prepontine cistern (subarachnoid space)	More definitive than EVD; avoids the need for a permanent VP shunt in many cases. Preferred in children > 6 months with obstructive hydrocephalus.
Ventriculoperitoneal (VP) shunt	Permanent CSF diversion from lateral ventricle to peritoneal cavity via subcutaneous tubing	Considered if ETV fails or is not feasible. Risk of shunt-related complications (infection, malfunction, overdrainage). CSF shunting for hydrocephalus (e.g., in posterior fossa lesions) ^[3]
High-dose glucocorticoids (dexamethasone)	Reduction of cerebral oedema ^[3] — dexamethasone stabilises the BBB → reduces vasogenic oedema surrounding the tumour → reduces mass effect → reduces ICP	IV or PO dexamethasone 10mg then 4mg Q4h or 8mg BD ^[3]. Note: dexamethasone reduces oedema, NOT the tumour itself. In PA, peritumoral oedema is typically mild, but dexamethasone may still provide symptomatic relief in acute presentations.
Head elevation (30°)	Promotes venous drainage via jugular veins → reduces intracranial blood volume → reduces ICP	Simple, immediate measure
Fluid resuscitation to maintain CPP	Keep MAP > 90 (to keep CPP ≥ 70 and ICP ≤ 20 mmHg) ^[12]	CPP = MAP − ICP. If ICP is raised, MAP must be maintained to ensure adequate cerebral perfusion.

Important Contraindication

C/I for dexamethasone: suspect CNS lymphoma → steroid causes acute lysis of lymphocytes → decreased diagnostic yield on biopsy ^[3]. This is not relevant in a child with typical PA on imaging, but if there is any diagnostic uncertainty (e.g., adult with an atypical-looking lesion where lymphoma is in the differential), obtain tissue before starting steroids.

3.2 Surgery — The Cornerstone of PA Management

Surgical: maximal safe removal as 1st line in all operable gliomas ^[3] Principle: maximal removal within safety limit ^[3] Aim: cytoreduction (decreased tumour mass) + functional preservation ^[3]

For PA specifically, the surgical goal is gross total resection (GTR) whenever safely achievable. Unlike high-grade gliomas where "complete resection" is nearly impossible due to diffuse infiltration, PA is well-circumscribed — it pushes brain tissue aside rather than infiltrating it. This makes GTR feasible in many cases, especially cerebellar PA.

Concept of 'resection margin' does not apply in neurosurgery ^[3] — this principle applies to high-grade diffuse gliomas. For PA, because the tumour is circumscribed, a "complete" resection of all visible tumour is the goal. There is no attempt to take "margins" of normal brain.

Approach	When Used	Details
Craniotomy	Most PAs — posterior fossa craniotomy for cerebellar PA	Flap of bone cut and reflected ^[3]. For posterior fossa PA, a suboccipital/posterior fossa craniotomy is performed. The patient is positioned prone or in the park-bench position. The bone flap is removed, the dura is opened, and the tumour is resected under microscopic or endoscopic guidance.
Burr hole	Stereotactic biopsy for inoperable tumours	Often for biopsy ^[3]. A small hole is drilled through the skull, and a biopsy needle is guided to the tumour using stereotactic coordinates.
Endoscopic approach	Selected intraventricular lesions, ETV	Minimally invasive; inserted through a burr hole; useful if tumour is accessible via the ventricular system
Skull base approaches	Brainstem/cervicomedullary PA	Complex approaches (e.g., retrosigmoid, far lateral) to access dorsally exophytic brainstem lesions

Image-guided surgery: ^[3]

Frameless stereotaxy: small skull markers allowing intraoperative localisation of handheld probe in relation to skull, tumour (localised in pre-op imaging) ± important structures (by fMRI or tractography) → guidance of resection

Real-time intra-operative imaging, e.g., by MRI (not available in HK)

Functional monitoring: ^[3]

Evoked potentials: detection of cortical electrical response to sensory stimuli or peripheral motor response to cortical electrical stimuli

Awake craniotomy: intraoperative electrical stimulation of cortex → observe speech response to map speech cortex → guide resection to avoid affecting speech (more relevant for supratentorial lesions near eloquent cortex; not typically used for cerebellar PA)

5-ALA-guided resection: ^[3]

Principle: 5-aminolevulinic acid (5-ALA) accumulated in tumour cells → intraoperative UV light application → tumour shows different colour — this is more commonly used in high-grade gliomas (GBM) but can occasionally be helpful in PA

Adjunct	How It Helps in PA Surgery
Neuronavigation (frameless stereotaxy)	Allows the surgeon to track instruments in real-time relative to pre-operative MRI → ensures complete tumour resection while avoiding critical structures (e.g., brainstem, dentate nucleus)
Intraoperative ultrasound	Real-time imaging to locate the tumour and confirm extent of resection during surgery — particularly useful for cystic PA where the mural nodule may be small
Intraoperative neurophysiology (evoked potentials)	SSEP and motor evoked potentials (MEPs) monitor the integrity of sensory and motor pathways during resection. If potentials change, the surgeon is warned that nearby critical tracts are at risk.
Intraoperative MRI	Gold standard for assessing completeness of resection during surgery — allows real-time adjustment. Not available in HK ^[3]

Location	GTR Achievable?	10-Year OS after GTR	Key Surgical Considerations
Cerebellar hemisphere	Yes, in > 90% of cases	> 95%	PA displaces rather than invades cerebellar tissue; the plane between tumour and normal brain is usually well-defined. GTR is often curative.
Cerebellar (near brainstem)	Partial in some cases	~85–90%	Proximity to brainstem limits extent of resection. Intraoperative monitoring essential.
Optic nerve (intraorbital)	Possible but sacrifices vision in that eye	Excellent	Complete resection involves removing the optic nerve → loss of vision in that eye. Only done if eye is already blind and there is progressive proptosis or risk to the chiasm.
Optic chiasm / hypothalamus	Usually NOT feasible for GTR	~85–90% with multimodal Rx	Resection risks devastating bilateral visual loss and hypothalamic injury (panhypopituitarism, obesity, memory impairment). Biopsy or debulking only.
Brainstem (dorsally exophytic)	Variable — GTR possible if exophytic	~85–90%	Exophytic component can be resected; intrinsic brainstem component is left.
Cerebral hemisphere	Yes, usually	> 95%	Similar to cerebellar PA; good outcomes with GTR
Spinal cord	Variable	Good	Intramedullary location; dissection plane may be less clear

High Yield — GTR vs STR and Prognosis

Gross total resection (GTR) is the single most important prognostic factor for cerebellar PA. After GTR, 10-year progression-free survival (PFS) is > 90–95%, and many patients are cured. After subtotal resection (STR), 10-year PFS drops to ~50–60% — residual tumour may remain stable for years or slowly progress. Post-operative MRI within 24–72 hours assesses extent of resection and guides further management.

Post-op complications of brain surgery ^[3]:

Complication	Mechanism	Management
Cerebellar mutism syndrome (posterior fossa syndrome)	Most feared complication of posterior fossa surgery in children (~25% incidence). Presents 1–2 days post-op with mutism, emotional lability, hypotonia, and ataxia. Thought to result from bilateral disruption of dentato-thalamo-cortical pathways.	Usually self-limiting (weeks to months) but speech may not fully recover. Supportive care and speech therapy.
Worsened ataxia	Surgical manipulation of cerebellar tissue; usually transient	Physiotherapy and rehabilitation
CSF leak / pseudomeningocele	Disruption of dural closure → CSF collects subcutaneously or leaks through the wound	May require lumbar drain or surgical re-exploration for dural repair
Infection (meningitis, wound infection)	Post-surgical bacterial contamination	Prophylactic antibiotics; treat with IV antibiotics if infection develops
Hydrocephalus (persistent post-op)	Pre-existing hydrocephalus may not resolve after tumour removal; or post-operative debris/blood blocks CSF flow	May require VP shunt or ETV
Haemorrhage (into tumour bed)	Surgical bed oozing	Post-op monitoring; may require re-exploration if expanding haematoma
Cranial nerve deficits (for brainstem PA)	Surgical manipulation near CN nuclei	Depends on which nerve; may be transient or permanent
Postoperative bleeding, CSF rhinorrhoea ^[13]	Particularly relevant for suprasellar/skull base approaches	CSF rhinorrhoea will require antibiotics to prevent ascending meningitis, as well as decision to go back to OT for repair ^[13]

Watchful waiting may be adopted in low-grade astrocytomas ^[3]

Indications for observation alone:

Scenario	Rationale
After GTR of cerebellar PA	GTR is often curative; surveillance MRI monitors for rare recurrence
NF1-associated OPG that is asymptomatic and non-progressive	Many NF1-OPGs remain indolent for years and some spontaneously regress. Treatment only when there is documented visual deterioration or tumour growth
Incidentally discovered PA (small, asymptomatic)	Small, asymptomatic tumours may be observed with serial MRI. PA grows very slowly due to oncogene-induced senescence
Stable residual after STR	If post-STR residual tumour is not growing on serial MRI, observation is preferred over subjecting a child to chemotherapy or radiotherapy

Surveillance protocol (typical):

MRI brain with contrast every 3 months for the first year
Then every 6 months for 2–3 years
Then annually for up to 10 years (or longer if residual tumour)
Ophthalmological assessment at every visit for OPG
Endocrine assessment annually if hypothalamic/suprasellar location

3.4 Systemic Therapy — Chemotherapy and Targeted Therapy

Systemic therapy is reserved for progressive or symptomatic PA that cannot be (further) resected. This typically applies to:

Optic pathway / hypothalamic PA — where surgery risks unacceptable functional damage
Recurrent / progressive PA after subtotal resection — where re-resection is not feasible
Disseminated PA — rare, with leptomeningeal spread

Regimen	Details	When Used
Carboplatin + Vincristine (CV)	Standard first-line chemotherapy for progressive paediatric low-grade glioma (including PA) for decades. Carboplatin = platinum agent causing DNA cross-links → cell death. Vincristine = vinca alkaloid binding tubulin → disrupts mitotic spindle → arrests cell division.	First-line for young children ( < 8–10 years) with progressive OPG or unresectable PA. Chosen to defer or avoid radiotherapy in young children (whose developing brain is most vulnerable to radiation damage).
Vinblastine monotherapy	Weekly IV vinblastine for prolonged duration (up to 68–70 weeks). Similar mechanism to vincristine (tubulin binding).	Alternative first-line or second-line; well-tolerated; used in multiple European and North American protocols
TPCV (thioguanine, procarbazine, lomustine, vincristine)	Multi-agent regimen	Second-line; used less frequently now with the advent of targeted therapy
Temozolomide	Oral alkylating agent. Temozolomide-based chemoradiation is standard for high-grade gliomas ^[3], but in PA it is occasionally used as a single agent for refractory cases.	Not standard first-line for PA; reserved for refractory cases

Why chemotherapy rather than radiotherapy in young children? The developing brain (especially in children < 8 years) is exquisitely sensitive to radiation damage. Radiotherapy to the optic pathway or hypothalamus can cause:

Neurocognitive decline (IQ loss, learning disabilities)
Secondary malignancies (radiation-induced meningioma, high-grade glioma — years to decades later)
Endocrinopathy (panhypopituitarism, growth failure)
Vasculopathy (Moyamoya syndrome)

Therefore, chemotherapy is used to delay or eliminate the need for radiotherapy, accepting that it is not curative but aims to stabilise/slow the disease.

This represents a paradigm shift in PA management. Because the MAPK pathway (RAS → RAF → MEK → ERK) is constitutively activated in virtually all PAs, drugs targeting this pathway are highly effective and far better tolerated than traditional chemotherapy.

Drug / Class	Target	Mechanism	Evidence / Indication
Selumetinib (MEK inhibitor)	MEK1/2	Blocks MEK → prevents ERK activation → stops cell proliferation. Does NOT require knowledge of the specific upstream alteration (works for BRAF fusion, BRAF V600E, NF1 loss — all converge on MEK)	FDA-approved (2020) for symptomatic, inoperable NF1-associated plexiform neurofibromas. Phase 3 trials (LOGGIC, PNOC) show superior response rates in paediatric LGG compared to carboplatin/vincristine. Increasingly used first-line.
Trametinib (MEK inhibitor)	MEK1/2	Same mechanism as selumetinib	Alternative MEK inhibitor; used in multiple international protocols
Dabrafenib (BRAF inhibitor)	BRAF V600E	Selectively inhibits V600E-mutant BRAF kinase → blocks downstream MEK/ERK signalling	Specifically for BRAF V600E-mutant PA (~5–10% of PA). NOT for BRAF fusion-positive PA (BRAF inhibitors can paradoxically activate MAPK in BRAF fusion tumours).
Dabrafenib + Trametinib (combined BRAF + MEK inhibition)	BRAF V600E + MEK	Dual blockade provides synergistic effect and reduces resistance	For BRAF V600E-mutant PA; mimics successful strategy in melanoma
Tovorafenib (type II RAF inhibitor)	All RAF isoforms (pan-RAF)	Unlike dabrafenib, tovorafenib does NOT cause paradoxical MAPK activation in BRAF fusion tumours → effective in both BRAF V600E AND BRAF-KIAA1549 fusion PA	FDA-approved (2024) for relapsed/refractory paediatric low-grade glioma with BRAF alteration — landmark FIREFLY-1 trial showed ~67% objective response rate. Given once weekly orally.
Larotrectinib / Entrectinib (NTRK inhibitors)	NTRK1/2/3 fusions	Inhibits tropomyosin receptor kinase (TRK) signalling → tumour-agnostic approach	For the rare PA with NTRK fusion

High Yield — The MAPK Targeted Therapy Revolution in PA

The management of progressive/unresectable PA has fundamentally changed between 2020 and 2026:

Before 2020: carboplatin/vincristine chemotherapy was the only first-line option for inoperable PA
2020–2024: MEK inhibitors (selumetinib, trametinib) emerged as superior alternatives in clinical trials
2024 onwards: Tovorafenib (pan-RAF inhibitor) became the first targeted therapy FDA-approved specifically for paediatric low-grade glioma — a landmark event

Key principle: always check molecular profiling before starting therapy — BRAF V600E tumours can receive BRAF inhibitors; BRAF fusion tumours should receive MEK inhibitors or pan-RAF inhibitors (NOT selective BRAF inhibitors which cause paradoxical MAPK activation in fusion tumours).

Why Can't You Give Dabrafenib to BRAF-KIAA1549 Fusion PA?

In BRAF-KIAA1549 fusion, the truncated BRAF protein dimerizes in a way that selective BRAF inhibitors (vemurafenib, dabrafenib) cannot effectively inhibit. Worse, binding of the inhibitor to one protomer of the dimer causes transactivation of the other protomer → paradoxical MAPK activation → tumour growth acceleration. This phenomenon is called "paradoxical ERK activation" and is well-described in melanoma with BRAF wild-type RAS-mutant tumours. For fusion-driven PA, use MEK inhibitors (downstream of BRAF) or pan-RAF inhibitors (tovorafenib, which inhibits both protomers of the dimer).

Drug Class	Common Side Effects	Mechanism
MEK inhibitors	Acneiform rash, diarrhoea, raised CK (rhabdomyolysis risk), periorbital oedema, retinal toxicity (central serous retinopathy), cardiac dysfunction (decreased LVEF)	MEK is expressed in normal skin, GI, muscle, and retina — inhibition affects these tissues
BRAF inhibitors	Pyrexia (very common with dabrafenib), arthralgia, fatigue, skin rash, squamous cell carcinoma/keratoacanthoma (paradoxical MAPK activation in BRAF-wildtype keratinocytes)	BRAF inhibitors activate MAPK in cells without BRAF mutation → keratinocyte proliferation
Pan-RAF inhibitors (tovorafenib)	Hair colour changes (depigmentation), rash, elevated CK, anaemia	RAF signalling is involved in melanocyte pigmentation pathways

3.5 Radiotherapy

Radiotherapy is NOT first-line for PA and is generally avoided in young children ( < 8–10 years). It is reserved for:

Indication	Rationale
Progressive PA refractory to both surgery and chemotherapy/targeted therapy	Last resort when other modalities have failed
Older children/adolescents/adults with unresectable progressive PA	When the risk-benefit balance favours radiation (developing brain is more mature; lower risk of neurocognitive effects)
Rare aggressive PA with malignant features	PA with anaplastic transformation (extremely rare) may benefit from radiation as used in higher-grade gliomas

Modality	Description	Advantage	Disadvantage
Conformal external beam radiotherapy (EBRT)	Precisely shaped radiation beams delivered to the tumour with minimal exposure to surrounding brain	Standard technique when RT is indicated	Still exposes some normal brain; risk of long-term side effects
Proton beam therapy	Uses protons instead of photons; protons deposit energy at a specific depth (Bragg peak) then stop → virtually no exit dose beyond the tumour	Minimal dose to surrounding normal brain — ideal for paediatric brain tumours near critical structures. Reduces long-term neurocognitive, endocrine, and secondary malignancy risk.	Limited availability (not currently available in Hong Kong as of 2026; nearest centres are in mainland China, Japan, and Singapore)
Stereotactic radiosurgery (SRS)	Single high-dose focused radiation delivered with extreme precision (e.g., Gamma Knife, CyberKnife)	SRS: as alternative to surgery if small/inoperable, or for small oligometastasis ( < 3 cm) ^[3]. Highly focused; minimal effect on surrounding brain.	Only suitable for small ( < 3 cm) tumours; not for large or cystic PA. Single fraction limits total dose.
Fractionated stereotactic radiotherapy (fSRT)	Multiple smaller doses delivered with stereotactic precision	Better for larger or more complex tumours where single-fraction SRS is not suitable	Multiple hospital visits

Late Effect	Mechanism	Why It Matters in PA
Neurocognitive decline	Damage to developing white matter, neural progenitor cells	PA patients have excellent long-term survival → they live long enough to suffer late effects. IQ drop of 2–5 points per year post-RT is documented in young children.
Endocrinopathy	Hypothalamic-pituitary axis damage	GH deficiency (most common), hypothyroidism, ACTH deficiency, precocious or delayed puberty
Secondary malignancy	Radiation-induced DNA damage in normal cells	Meningioma, high-grade glioma, sarcoma — can appear 10–30 years post-RT
Vasculopathy (Moyamoya)	Radiation damage to intracranial arteries	Progressive stenosis of internal carotid/MCA → ischaemic strokes. Risk highest when RT given to young children, especially those with NF1.
Hearing loss	If cochlea in radiation field (posterior fossa RT)	Sensorineural hearing loss
Cataracts	Lens irradiation (if near orbit)	Posterior subcapsular cataracts

Why Radiotherapy Is Avoided in Young Children with PA

PA has > 95% long-term survival. If you irradiate a 3-year-old's brain, they will live long enough to develop devastating late effects — neurocognitive decline, secondary cancers, vasculopathy, and endocrinopathy. The whole point of using chemotherapy or targeted therapy first is to buy time until the child is older (ideally > 8–10 years) when the brain is more resilient to radiation, or ideally to avoid radiation entirely.

Location	First-Line Management	Second-Line if Progressive	Role of RT
Cerebellar PA	Maximal safe surgical resection (GTR)	Re-resection → targeted therapy / chemotherapy	Rarely needed; reserved for multiply recurrent disease
Optic pathway / Hypothalamic PA (NF1)	Observation if asymptomatic. If progressive: targeted therapy (MEK inhibitor) or carboplatin/vincristine	Alternative targeted therapy, vinblastine, clinical trial	Deferred as long as possible; proton beam if needed
Optic pathway / Hypothalamic PA (sporadic)	Surgery (debulking if safe) + observation. If progressive: same as NF1-associated	Same as above	Same as above
Brainstem (exophytic)	Surgical resection of exophytic component	Targeted therapy / chemotherapy for progressive residual	Reserved for refractory cases
Cerebral hemisphere	Maximal safe surgical resection (GTR)	Similar to cerebellar PA	Rarely needed
Spinal cord	Maximal safe surgical resection	Targeted therapy / chemotherapy	Reserved for refractory cases

Anticonvulsants: treatment or secondary prophylaxis of seizures, usually levetiracetam (Keppra) ^[3] NOT for infratentorial lesions, usually not for primary prophylaxis ^[3]

Point	Explanation
Seizures only occur with supratentorial PA	Infratentorial (cerebellar) cortex is inhibitory in nature ^[3] — it does not generate seizures. Therefore, AEDs are NOT indicated for cerebellar PA.
Drug of choice: levetiracetam	Broad-spectrum, well-tolerated, does NOT induce cytochrome P450 enzymes (important because enzyme inducers like phenytoin or carbamazepine can interact with chemotherapy drugs or dexamethasone)
Primary prophylaxis not recommended	Routine AED use in brain tumour patients without seizures does NOT reduce seizure risk and carries unnecessary side effects

Domain	Interventions	Rationale
Endocrine	Hormone replacement therapy (GH, thyroid, cortisol, sex hormones)	Hypothalamic/pituitary damage from tumour or treatment
Ophthalmology	Regular visual assessment, low vision aids	Monitor and support visual function in OPG
Physiotherapy	Gait training, balance exercises, coordination exercises	Post-operative cerebellar dysfunction (ataxia), cerebellar mutism recovery
Speech therapy	Articulation therapy, AAC devices	Cerebellar mutism syndrome, dysarthria
Neuropsychology	Cognitive assessment, educational support, IEP (individualised education plan)	Monitor for neurocognitive effects of tumour and treatment
Psychosocial	Counselling for child and family, peer support	Long-term chronic illness management, anxiety, school reintegration
Nutrition / Endocrine	Dietetics input, obesity management	Hypothalamic obesity (very difficult to treat — resistant to diet and exercise due to disrupted satiety signalling; may respond to octreotide or bariatric surgery in extreme cases)

Scenario	10-Year Overall Survival	10-Year PFS	Key Determinant
Cerebellar PA with GTR	> 95%	> 90%	Completeness of resection is the strongest prognostic factor
Cerebellar PA with STR	~90%	~50–60%	Residual tumour may progress; requires surveillance and potential re-intervention
Optic pathway/hypothalamic PA	~85–90%	~40–50% (many require treatment)	Location prevents GTR; functional outcomes (vision, endocrine) are the main concern
NF1-associated OPG	~95%	Variable	Generally better prognosis than sporadic OPG; many remain indolent
PA with leptomeningeal dissemination	~70–80%	Lower	Rare; requires more aggressive systemic therapy

High Yield Summary — Management of Pilocytic Astrocytoma

Surgical resection (maximal safe removal) is the cornerstone — GTR is curative for cerebellar PA in > 90–95% of cases.
Observation is appropriate for: asymptomatic NF1-associated OPG, stable residual after STR, incidental small PA.
Emergency management: CSF diversion (EVD or ETV) for obstructive hydrocephalus before definitive surgery. Dexamethasone reduces cerebral oedema but does NOT treat the tumour.
Chemotherapy (carboplatin/vincristine) was traditional first-line systemic therapy for progressive/unresectable PA, aimed at deferring radiotherapy in young children.
Targeted therapy (MEK inhibitors — selumetinib, trametinib; pan-RAF inhibitor — tovorafenib) is now first-line for progressive PA — superior efficacy and tolerability. Tovorafenib was FDA-approved in 2024 for relapsed paediatric LGG.
BRAF V600E-mutant PA can receive dabrafenib ± trametinib. BRAF fusion PA should NOT receive selective BRAF inhibitors (paradoxical MAPK activation) — use MEK inhibitors or tovorafenib instead.
Radiotherapy is deferred or avoided in young children due to devastating long-term effects (neurocognitive decline, secondary malignancy, endocrinopathy, vasculopathy). Reserved as last resort.
AEDs (levetiracetam) are only for supratentorial PA with seizures — NOT for cerebellar PA, and NOT for primary prophylaxis.
Multidisciplinary rehabilitation is essential: physiotherapy, speech therapy (cerebellar mutism), endocrine replacement, ophthalmology, neuropsychology.
Post-operative MRI within 24–72 hours determines GTR vs STR and guides all subsequent management decisions.

Active Recall - Management of Pilocytic Astrocytoma

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, p.1258–1260 (Features of different brain tumours — Astrocytomas) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, p.530 (Features of different brain tumours — Astrocytomas) ^[3] Senior notes: Ryan Ho Neurology.pdf, p.163–165 (Intracranial Tumours — Management: medical therapy, surgery, operative techniques, gliomas, brain metastasis Mx) ^[12] Senior notes: Maksim Medicine Notes.pdf, p.278 (Increased ICP — Management, ICP monitoring, EVD) ^[13] Senior notes: Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf, p.11 (Treatment of pituitary tumours — surgical complications)

Complications of Pilocytic Astrocytoma

Complications of pilocytic astrocytoma can be organised into three categories: (A) complications of the tumour itself, (B) complications of treatment, and (C) long-term sequelae and late effects. Because PA has excellent survival ( > 95% at 10 years), the focus in modern practice has shifted from survival to minimising treatment-related morbidity — the child will live with the consequences of both the disease and its treatment for decades.

1. Complications of the Tumour Itself

Complication	Pathophysiological Basis	Clinical Consequences
Obstructive (non-communicating) hydrocephalus	Posterior fossa PA compresses or obstructs the 4th ventricle and/or cerebral aqueduct of Sylvius → CSF cannot flow from the 3rd ventricle to the subarachnoid space → upstream dilatation of lateral and 3rd ventricles → raised ICP	Headache (worse in morning), vomiting, papilloedema, 6th nerve palsy (false localising sign — CN VI has longest intracranial course, most susceptible to stretch), decreased consciousness. In infants: bulging fontanelle, macrocephaly, sun-setting sign.
Brain herniation	If raised ICP is left untreated, brain tissue is displaced across rigid dural partitions → uncal herniation (temporal lobe through tentorial notch → CN III compression → ipsilateral fixed dilated pupil, contralateral hemiparesis) or tonsillar herniation (cerebellar tonsils through foramen magnum → brainstem compression → respiratory arrest, death)	Brain herniation ^[3] is the ultimate lethal complication of untreated posterior fossa PA with hydrocephalus. Cushing's triad (systemic hypertension, bradycardia, respiratory depression) is a late, pre-terminal sign ^[3].
Chronic raised ICP — visual loss	Sustained papilloedema → chronic optic nerve fibre damage → optic atrophy → permanent blindness if not relieved	This is why urgent CSF diversion (EVD or ETV) is critical in acute presentations

Key Teaching Point

The paradox of PA: it is a biologically benign, WHO Grade 1 tumour, but if the hydrocephalus it causes is not recognised and treated promptly, the patient can die from tonsillar herniation. Location matters more than histological grade in determining acute danger.

Complications of optic pathway glioma (PA): visual loss, premature or delayed puberty (if involving hypothalamus) ^[4]^[9]

Complication	Pathophysiology	Details
Progressive visual loss	Direct compression and infiltration of optic nerve fibres by the expanding tumour → Wallerian degeneration → irreversible visual loss once nerve fibres die	Often insidious in young children (may not complain until severely impaired). Bilateral visual loss can occur if the chiasm is involved. Visual loss may be the presenting feature or may progress despite treatment.
Visual field deficits	Depends on location along the optic pathway: optic nerve → monocular loss; chiasm → bitemporal hemianopia; tract → homonymous hemianopia	Bitemporal hemianopia from chiasmal compression affects peripheral/temporal vision bilaterally → the child bumps into things on both sides
Optic atrophy	Chronic compression → irreversible nerve fibre loss → pale optic disc on fundoscopy	Indicates established, irreversible damage. Once optic atrophy is present, vision cannot be recovered even if the tumour is treated.
Nystagmus and strabismus	Disruption of visual input → sensory deprivation nystagmus; or direct involvement of visual-vestibular pathways	May lead to amblyopia ("lazy eye") if present in early childhood and not managed

Complication	Pathophysiology	Clinical Features
Growth hormone deficiency	Hypothalamic or pituitary stalk disruption → reduced GHRH stimulation of anterior pituitary somatotrophs → decreased GH → decreased hepatic IGF-1 production	Short stature, decreased growth velocity, delayed bone age. Most common anterior pituitary hormone to be affected because GH-producing cells are the most sensitive to damage.
Premature puberty ^[4]^[9]	Mass effect on the hypothalamus may stimulate GnRH release (disruption of inhibitory pathways that normally suppress GnRH in prepubertal children) → pulsatile LH/FSH release → sex steroid production → premature sexual maturation	Central precocious puberty: breast development ( < 8 y in girls), testicular enlargement ( < 9 y in boys), pubic hair, growth spurt followed by early epiphyseal fusion → short adult height
Delayed puberty ^[4]^[9]	Alternatively, destruction of GnRH neurons → absent or reduced pulsatile LH/FSH → hypogonadotropic hypogonadism	Absent pubertal development by age 13 (girls) or 14 (boys); requires sex steroid replacement
Hypothalamic obesity	Destruction of the ventromedial hypothalamic satiety centre → hyperphagia and autonomic dysregulation → excessive weight gain refractory to diet/exercise	One of the most devastating long-term complications. Patients can gain massive amounts of weight. Extremely difficult to treat — standard dietary measures and exercise fail because the hypothalamic "set point" is disrupted.
Diencephalic syndrome (in infants)	Disruption of hypothalamic metabolic regulation → paradoxical emaciation despite adequate caloric intake; may involve GH hypersecretion and altered autonomic tone	Failure to thrive, hyperactivity, euphoria in an infant with a hypothalamic mass. Can be mistaken for neglect or malabsorption.
Diabetes insipidus (DI)	Damage to ADH (vasopressin)-producing neurons in the supraoptic and paraventricular nuclei of the hypothalamus, or disruption of the hypothalamo-neurohypophyseal tract	Polyuria (dilute urine, low osmolality), polydipsia, hypernatraemia if fluid intake is inadequate. Less common with PA (more associated with craniopharyngioma and germinoma), but can occur.
Panhypopituitarism	Extensive hypothalamic/pituitary stalk damage → loss of all anterior pituitary hormones: GH, TSH, ACTH, LH/FSH, prolactin	Requires lifelong multi-hormone replacement: hydrocortisone (cortisol), levothyroxine (T4), growth hormone, sex steroids. ACTH deficiency is life-threatening (adrenal crisis).

Low metastatic potential with only small proportion of tumours that progress and develop meningeal spread particularly when occurring in the optic path region ^[1]^[2]

Aspect	Details
Frequency	Rare overall ( < 5% of PA); more common with optic pathway/hypothalamic PA and the pilomyxoid astrocytoma variant
Mechanism	Tumour cells shed into the CSF → disseminate along the craniospinal subarachnoid space → "drop metastases" to the spinal cord surface, nerve roots, or distant intracranial sites
Consequences	Spinal cord compression, multiple cranial nerve palsies, communicating hydrocephalus (tumour cells clog arachnoid granulations → impaired CSF absorption)
Prognosis	Significantly worse than localised PA; requires more aggressive treatment (craniospinal radiotherapy ± intensified chemotherapy)

Rarely invasive and rarely undergoes malignant transformation into more aggressive tumour ^[1]^[2]

PA can, in exceedingly rare instances ( < 2%), transform into a higher-grade glioma (e.g., anaplastic astrocytoma or glioblastoma)
Molecularly, this is associated with loss of oncogene-induced senescence (OIS) — specifically, CDKN2A/p16 homozygous deletion removes the cell-cycle brake that keeps PA indolent → unrestrained proliferation
Some series suggest that prior radiotherapy may increase the risk of malignant transformation (radiation-induced additional mutations), though causality is difficult to prove
Clinically: a previously stable PA that suddenly begins to grow rapidly or shows new areas of necrosis/restricted diffusion on MRI should raise suspicion → re-biopsy is indicated

2. Complications of Treatment

Posterior fossa syndrome (cerebellar mutism): ^[14]^[15]

Postoperative complication caused by injury to cerebellar vermis or dentate nuclei during resection of tumours in midline cerebellum

Appears 1–2 days after surgery and resolves within weeks to months

Characterised by impaired language production with emotional lability

Complication	Incidence	Pathophysiology	Management
Cerebellar mutism syndrome / Posterior fossa syndrome	~25% of posterior fossa surgery in children ^[14]^[15]	Bilateral disruption of efferent cerebellar pathways, particularly the dentato-thalamo-cortical tract connecting the dentate nuclei to the supplementary motor area (SMA) and prefrontal cortex via the superior cerebellar peduncle and ventrolateral thalamus. The SMA is critical for speech initiation. Injury to both sides (during midline approach) → complete inability to initiate speech.	Supportive: speech therapy, physiotherapy. Most recover speech over weeks to months, but some children have permanent dysarthria or cognitive deficits. No specific pharmacotherapy proven effective.
Post-operative ataxia	Very common (most patients have transient worsening)	Surgical manipulation and retraction of cerebellar tissue; disruption of cerebellar circuitry	Usually improves with time and physiotherapy. May persist if deep cerebellar nuclei are damaged.
Cranial nerve deficits	Variable; depends on tumour proximity to brainstem	Direct injury to cranial nerve nuclei or their intraparenchymal fibres during resection of brainstem-adjacent PA	CN VI (abducens) and CN VII (facial) palsies most common in posterior fossa surgery. May be transient or permanent.
CSF leak / pseudomeningocele	~5–10%	Disruption of dural closure after posterior fossa craniotomy → CSF tracks subcutaneously (pseudomeningocele) or leaks through wound/nose (if skull base approach)	CSF rhinorrhoea will require antibiotics to prevent ascending meningitis, as well as decision to go back to OT for repair ^[13]. Pseudomeningocele may resolve spontaneously or require surgical revision.
Post-operative haemorrhage	~1–3%	Bleeding from the tumour bed, especially if the mural nodule was highly vascular	Monitor with post-operative CT if clinical deterioration. May require emergency re-exploration.
Meningitis / wound infection	~2–5%	Bacterial contamination during surgery; CSF leak providing a conduit for ascending infection	Prophylactic antibiotics peri-operatively; IV antibiotics if infection develops
Persistent hydrocephalus	~20–30% of posterior fossa tumour surgery	Pre-existing hydrocephalus may not resolve after tumour removal (due to chronic changes in CSF dynamics); or blood/debris blocks CSF pathways post-operatively	May require VP shunt or ETV. Some centres place an EVD prophylactically at surgery to manage CSF temporarily.
New neurological deficit (hemiparesis, visual field cut)	Rare in PA surgery (more common in supratentorial/eloquent cortex surgery)	Injury to adjacent brain parenchyma or vascular damage (infarction from perforator injury)	Depends on deficit; rehabilitation

Drug	Key Toxicities	Pathophysiological Basis
Carboplatin	Myelosuppression (neutropaenia, thrombocytopaenia, anaemia); hypersensitivity reactions (up to 40% after repeated cycles); ototoxicity (high-frequency hearing loss); nephrotoxicity (milder than cisplatin)	Platinum agents form DNA cross-links in rapidly dividing cells (bone marrow, cochlear hair cells, renal tubular cells). Hypersensitivity is IgE-mediated (Type I) developing after repeated exposure.
Vincristine	Peripheral neuropathy (sensory > motor; foot drop, paraesthesias, constipation from autonomic neuropathy); jaw pain; SIADH	Vincristine disrupts microtubule assembly → affects axonal transport in peripheral nerves → neuropathy. GI dysmotility from autonomic nerve damage → constipation (can be severe, ileus).
Vinblastine	Myelosuppression (dose-limiting); less neuropathic than vincristine	Similar mechanism to vincristine but relatively more marrow-toxic and less neurotoxic

Chemotherapy complications [for medulloblastoma, but relevant principles for all paediatric brain tumour chemotherapy]: ototoxicity (Cisplatin-induced) ^[14]^[15]

These are the most feared long-term complications, which is why radiotherapy is deferred or avoided in young children with PA whenever possible:

Radiotherapy complications: ^[14]^[15]

Ototoxicity

Short stature (decreased GH)

Endocrine abnormalities (decreased GH (94%) / ACTH (43%) / TSH (10%))

Cerebrovascular abnormalities (Stroke / Intracranial haemorrhage)

Late Effect	Latency	Pathophysiology	Clinical Impact
Neurocognitive decline	Months to years	Radiation damages proliferating oligodendrocyte precursor cells and neural stem cells (particularly in the hippocampus and subventricular zone) → impaired myelination → white matter injury → progressive cognitive decline	IQ drop of 2–5 points per year post-RT documented in young children. Affects attention, processing speed, working memory. Younger age at RT = worse outcome (developing brain is more vulnerable).
Endocrinopathy	Months to years	Hypothalamic-pituitary axis is exquisitely radiosensitive. GH-producing somatotrophs are the most vulnerable (lowest radiation threshold). Progressive destruction of hormone-producing cells in a dose-dependent fashion.	Decreased GH is the most common (94%) ^[14]^[15] → growth failure. Decreased ACTH (43%) → secondary adrenal insufficiency (risk of adrenal crisis). Decreased TSH (10%) → central hypothyroidism. Also: precocious puberty (low-dose RT can paradoxically stimulate GnRH neurons before eventually destroying them).
Short stature	Years	GH deficiency + direct radiation damage to vertebral growth plates (if craniospinal RT)	Short stature (decreased GH) ^[14]^[15]. Compounded by spinal irradiation which directly damages vertebral body epiphyseal plates. Requires GH replacement therapy.
Secondary malignancy	5–30 years	Radiation causes DNA double-strand breaks in normal cells → mutagenesis → secondary neoplasm. Risk is dose-dependent and highest in young children.	Radiation-induced meningioma (most common secondary CNS tumour), high-grade glioma, sarcoma within the radiation field. Lifetime incidence: ~3–5% at 30 years post-RT. This is particularly tragic because the original PA had excellent survival — the child is "cured" of PA but develops a radiation-induced cancer decades later.
Cerebrovascular abnormalities	Years	Radiation causes endothelial damage and intimal fibrosis in cerebral arteries → progressive stenosis, particularly of the intracranial internal carotid artery and Circle of Willis → Moyamoya syndrome (progressive bilateral ICA stenosis with collateral "puff of smoke" vessels)	Stroke / Intracranial haemorrhage ^[14]^[15]. Risk is highest in children who receive RT to the optic pathway/hypothalamus (Willis circle is in the radiation field) and those with NF1 (who already have an increased baseline risk of cerebrovascular dysplasia — cerebrovascular dysplasia (2–6%) including Moyamoya ^[9]).
Ototoxicity	Weeks to months	Damage to cochlear hair cells (inner ear is radiosensitive)	Ototoxicity ^[14]^[15]. Sensorineural hearing loss, especially high-frequency. Compounded if cisplatin-based chemotherapy is also used.
Cataracts	1–5 years	Radiation damage to the lens epithelium → posterior subcapsular cataract	If orbit/periorbital area is in the radiation field (optic pathway PA RT)
Hypothalamic obesity	Months to years	Radiation damage to the ventromedial hypothalamic satiety centre — same mechanism as tumour-related hypothalamic obesity but iatrogenic	Intractable weight gain; resistant to conventional management

High Yield — Why Late Effects of RT Are So Important in PA

PA patients survive for decades. A 5-year-old cured of cerebellar PA will live to 75+. If they received cranial RT, they face 50+ years of accumulated risk from radiation late effects. This is why the entire thrust of modern PA management is to use surgery and targeted therapy to avoid radiation entirely in as many patients as possible. The late effects of RT often cause more morbidity than the original tumour.

Drug Class	Specific Complications	Mechanism	Management
MEK inhibitors (selumetinib, trametinib)	Acneiform rash; cardiac dysfunction (decreased LVEF, cardiomyopathy); retinal toxicity (central serous retinopathy, retinal vein occlusion); elevated CK / rhabdomyolysis; diarrhoea; periorbital oedema	MEK is expressed in normal cardiomyocytes, retinal pigment epithelium, skin, and muscle. Inhibition of MEK in these tissues causes on-target off-tumour effects.	Regular echocardiography (cardiac monitoring); ophthalmological assessment; CK monitoring; dermatological management of rash
BRAF inhibitors (dabrafenib)	Pyrexia (most common, can be severe); arthralgia; cutaneous squamous cell carcinoma / keratoacanthoma (paradoxical MAPK activation in BRAF-wildtype keratinocytes); photosensitivity	BRAF inhibitors block BRAF signalling in tumour cells but paradoxically activate the MAPK pathway in normal cells with wildtype BRAF → keratinocyte proliferation → skin SCC. Pyrexia mechanism is unclear, possibly cytokine-mediated.	Skin surveillance for SCC; antipyretics for pyrexia; sun protection
Pan-RAF inhibitor (tovorafenib)	Hair colour changes (depigmentation/whitening); CK elevation; rash; anaemia; hepatotoxicity	RAF signalling is involved in melanocyte differentiation and pigmentation → inhibition causes hair depigmentation. Mechanism of CK elevation similar to MEK inhibitors.	Reversible upon drug discontinuation; regular blood monitoring

Important Exam Note

Targeted therapy side effects are increasingly exam-relevant as these drugs become standard of care. The key principle: MAPK pathway drugs have on-target off-tumour effects in tissues that normally use the same signalling pathway (skin, heart, retina, muscle). The side effects are mechanistically predictable once you understand the pathway.

Because PA patients have excellent long-term survival, survivorship issues dominate the clinical picture:

Domain	Specific Issues	Why It Occurs
Neurocognitive	Learning difficulties, attention deficits, reduced processing speed, executive dysfunction	Combination of: tumour effects on developing brain, hydrocephalus (chronic ventricular dilatation stretches periventricular white matter), surgery (cerebellar cognitive affective syndrome), and/or radiotherapy
Cerebellar cognitive affective syndrome (CCAS)	Executive dysfunction, impaired spatial cognition, personality change (blunted affect or disinhibition), language deficits	Originally described by Schmahmann — the cerebellum is now recognised as contributing to cognition and emotion, not just motor coordination. Damage to the posterior lobe and vermis (from tumour or surgery) disrupts cerebello-cortical circuits that modulate prefrontal and limbic function.
Persistent ataxia / motor deficit	Gait instability, fine motor incoordination	Residual cerebellar damage from tumour and/or surgery. May improve with rehabilitation but some degree of deficit often persists.
Hearing loss	Sensorineural hearing loss	Cisplatin-based chemotherapy; posterior fossa radiotherapy; direct surgical trauma to CN VIII
Psychosocial	Anxiety, depression, social isolation, reduced quality of life, impaired school performance	Chronic illness during formative childhood years; altered appearance (surgical scar, hair loss); neurocognitive limitations; frequent hospital visits
Fertility	Reduced fertility if hypothalamic-pituitary-gonadal axis damaged; gonadal damage from alkylating chemotherapy	Hypothalamic PA or its treatment → hypogonadism. Alkylating agents (if used) directly damage gonadal germ cells.
Second neoplasms	Radiation-induced meningioma, high-grade glioma; chemotherapy-related secondary leukaemia (rare with PA regimens)	As above
Epilepsy	Chronic seizure disorder (if supratentorial PA or post-surgical gliosis)	Gliosis → increased risk of epilepsy ^[3]. Cortical gliosis (scarring) creates epileptogenic foci — abnormal synchronous neuronal firing at the scar border.
Recurrence	Tumour regrowth at the original site, especially after subtotal resection	PA grows slowly but persistent residual after STR can reactivate. Recurrence rate after STR is ~40–50% over 10 years; after GTR, recurrence is < 5–10%.

Category	Major Complications	Key Points
Tumour-related	Obstructive hydrocephalus/raised ICP → brain herniation; visual loss (OPG); endocrinopathy (hypothalamic PA); leptomeningeal dissemination (rare); malignant transformation (extremely rare)	Location determines complication profile: posterior fossa = hydrocephalus; optic pathway = vision; hypothalamus = endocrine
Surgery-related	Cerebellar mutism syndrome (appears 1–2 days post-op, resolves weeks–months) ^[14]^[15]; post-op ataxia; CN palsies; CSF leak; infection; haemorrhage; persistent hydrocephalus	Cerebellar mutism is the most feared surgical complication in children; caused by bilateral dentato-thalamo-cortical tract injury
Chemotherapy-related	Myelosuppression; carboplatin hypersensitivity; vincristine neuropathy; ototoxicity (cisplatin)	Chemotherapy is used to defer/avoid RT; side effects are generally manageable and reversible
Radiotherapy-related	Neurocognitive decline; endocrinopathy (GH deficiency 94%, ACTH 43%, TSH 10%); short stature; cerebrovascular abnormalities (Moyamoya, stroke); ototoxicity; secondary malignancy ^[14]^[15]	Most devastating long-term complications; main reason RT is avoided in young children
Targeted therapy-related	MEK inhibitor: cardiac, retinal, skin, CK elevation; BRAF inhibitor: pyrexia, skin SCC; Pan-RAF: hair depigmentation	On-target off-tumour effects; reversible with dose modification/cessation
Long-term survivorship	Neurocognitive deficits; CCAS; psychosocial issues; epilepsy; fertility; recurrence	Survivorship care is as important as cancer treatment in PA

High Yield Summary — Complications of Pilocytic Astrocytoma

Obstructive hydrocephalus is the most dangerous acute complication — posterior fossa PA compresses the 4th ventricle → raised ICP → risk of tonsillar herniation and death if untreated.
Visual loss is the most important complication of optic pathway PA — often insidious in young children; optic atrophy indicates irreversible damage.
Endocrine dysfunction complicates hypothalamic PA: GH deficiency (short stature), precocious/delayed puberty, hypothalamic obesity (intractable), and rarely diabetes insipidus.
Cerebellar mutism syndrome (posterior fossa syndrome) affects ~25% of children after posterior fossa surgery — caused by bilateral dentato-thalamo-cortical tract injury; usually self-limiting but speech recovery may be incomplete.
Radiotherapy late effects are the most feared long-term complications: neurocognitive decline (2–5 IQ points/year), endocrinopathy (GH deficiency in 94%), secondary malignancy (meningioma, HGG), cerebrovascular Moyamoya (especially in NF1 patients), and ototoxicity. This is why RT is deferred/avoided in young children.
Malignant transformation is extremely rare ( < 2%) and is associated with CDKN2A/p16 loss (escape from oncogene-induced senescence). Suspect if a previously stable PA suddenly grows rapidly.
Leptomeningeal dissemination is uncommon but occurs more in optic pathway PA and the pilomyxoid variant.
Long-term survivorship issues (neurocognitive, psychosocial, endocrine, fertility) are critical because PA patients live for decades — survivorship care is as important as acute cancer treatment.

Active Recall - Complications of Pilocytic Astrocytoma

References

^[1] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, p.1258–1260 (Features of different brain tumours — PA: low metastatic potential, rarely invasive, rarely malignant transformation) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, p.530 (Features of different brain tumours — PA: low metastatic potential, rarely invasive, rarely malignant transformation) ^[3] Senior notes: Ryan Ho Neurology.pdf, p.151, 163, 165 (Brain tumours — Management, post-op complications, gliosis and epilepsy, brain herniation) ^[4] Senior notes: Ryan Ho Rheumatology.pdf, p.171–172 (NF1 — Optic pathway glioma complications: visual loss, premature or delayed puberty) ^[9] Senior notes: Adrian Lui Pediatrics Notes.pdf, p.148 (NF1 — OPG complications, cerebrovascular dysplasia including Moyamoya) ^[13] Senior notes: Block A - I keep on bumping into people on my side: pituitary tumours; hypopituitarism.pdf, p.11 (Surgical complications — CSF rhinorrhoea, postoperative bleeding) ^[14] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf, p.1262–1264 (Treatment of medulloblastoma — surgical complications including posterior fossa syndrome/cerebellar mutism; RT complications including ototoxicity, short stature, endocrine abnormalities, cerebrovascular abnormalities) ^[15] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf, p.534 (Treatment of medulloblastoma — identical content: surgical and RT complications)

High Yield Summary

Pilocytic astrocytoma (PA) is the most common astrocytoma in children, classified as WHO Grade 1 — circumscribed, slow-growing, excellent prognosis.
Classical location is the cerebellum (60%), followed by the optic pathway/hypothalamus (25–30%). Can occur anywhere in the CNS.
Molecular hallmark: constitutive MAPK pathway activation — most commonly via BRAF-KIAA1549 fusion (70–80% of cerebellar PA). NF1-associated PA involves loss of neurofibromin (RAS-GAP).
NF1 association: ~50% of optic pathway gliomas occur in NF1 patients; the pathology is typically pilocytic astrocytoma. Screen NF1 children with annual ophthalmological assessment.
Rarely invasive, rarely undergoes malignant transformation — explained by oncogene-induced senescence (OIS).
Clinical presentation: (a) Raised ICP — headache (worse in morning), vomiting, papilloedema — from obstructive hydrocephalus (4th ventricle compression); (b) Cerebellar signs — ataxia (truncal > appendicular for vermian lesions), dysmetria, nystagmus, dysarthria; (c) Visual loss/field defects — for optic pathway PA; (d) Endocrine dysfunction — for hypothalamic PA.
Histological hallmarks: biphasic pattern (compact piloid + loose microcystic areas), Rosenthal fibres, eosinophilic granular bodies, low mitotic rate.
MRI appearance: well-circumscribed cystic lesion with brightly enhancing mural nodule. Minimal oedema. No restricted diffusion (helps distinguish from medulloblastoma).
WHO Astrocytoma Grading: Grade 1 (PA/SEGA) → Grade 2 (diffuse/pilomyxoid) → Grade 3 (anaplastic) → Grade 4 (GBM). Low-grade = Grade 1+2; High-grade = Grade 3+4.
Posterior fossa tumours in children (the "Big 3"): PA (most common), medulloblastoma, ependymoma. Location, age, and imaging features help differentiate.

High Yield Summary — Differential Diagnosis of Pilocytic Astrocytoma

The DDx depends on location: posterior fossa → medulloblastoma, ependymoma, AT/RT, haemangioblastoma, DIPG; optic pathway/suprasellar → craniopharyngioma, germinoma, LCH, hypothalamic hamartoma; supratentorial → diffuse astrocytoma, oligodendroglioma, ganglioglioma, PXA.
"Big Three" paediatric posterior fossa tumours: PA (lateral hemisphere, cystic + mural nodule, no restricted diffusion), medulloblastoma (midline vermis, solid, restricted diffusion, leptomeningeal spread), ependymoma (4th ventricle floor, "plastic", extends through foramina).
Calcification on CT in a suprasellar mass = craniopharyngioma until proven otherwise.
DWI is the single most useful MRI sequence for posterior fossa DDx: restricted diffusion → medulloblastoma or abscess; no restriction → PA.
NF1 UBOs (unidentified bright objects) are T2-hyperintense foci that are NOT tumours and must not be confused with PA.
Haemangioblastoma mimics cerebellar PA perfectly (cystic + mural nodule) but occurs in young adults, has flow voids, and is associated with VHL syndrome.
Turcot syndrome (FAP variant) is associated with medulloblastoma (WNT subgroup).
Brain abscess mimics ring-enhancing tumour but has restricted diffusion within the cystic cavity (pus restricts water movement).

High Yield Summary — Diagnosis of Pilocytic Astrocytoma

Diagnosis requires integration of imaging + histopathology + molecular profiling (WHO CNS5 integrated diagnosis). There are no standalone "diagnostic criteria" like rheumatic fever.
MRI brain with gadolinium is the gold standard imaging modality — look for cystic + enhancing mural nodule (cerebellar PA) or fusiform optic nerve thickening (OPG).
DWI is the key differentiating MRI sequence: no restricted diffusion in PA vs restricted diffusion in medulloblastoma and abscess.
CT is for triage — fast, detects hydrocephalus and calcification, but inferior to MRI for tumour characterization.
Normal brain tissue does not enhance on contrast CT/MRI because of the intact BBB; enhancement implies BBB disruption (tumour, inflammation) or structures outside the BBB (meninges).
NF1-associated OPG does not require biopsy — diagnosis is clinical + radiological in a child meeting NF1 criteria (CAFESPOT: ≥ 2 of 7).
Molecular markers that MUST be negative in PA: IDH mutation, H3K27M mutation, 1p/19q co-deletion, CDKN2A homozygous deletion. If any are present → reclassify.
BRAF-KIAA1549 fusion (~70–80% of cerebellar PA) is near-pathognomonic and therapeutically actionable (MEK/BRAF inhibitors).
Post-operative MRI within 24–72 hours is essential to assess extent of resection (GTR vs STR) before post-surgical changes obscure the field.
LP is contraindicated if raised ICP with risk of herniation — obtain CSF intra-operatively or after CSF diversion.

High Yield Summary — Management of Pilocytic Astrocytoma

Surgical resection (maximal safe removal) is the cornerstone — GTR is curative for cerebellar PA in > 90–95% of cases.
Observation is appropriate for: asymptomatic NF1-associated OPG, stable residual after STR, incidental small PA.
Emergency management: CSF diversion (EVD or ETV) for obstructive hydrocephalus before definitive surgery. Dexamethasone reduces cerebral oedema but does NOT treat the tumour.
Chemotherapy (carboplatin/vincristine) was traditional first-line systemic therapy for progressive/unresectable PA, aimed at deferring radiotherapy in young children.
Targeted therapy (MEK inhibitors — selumetinib, trametinib; pan-RAF inhibitor — tovorafenib) is now first-line for progressive PA — superior efficacy and tolerability. Tovorafenib was FDA-approved in 2024 for relapsed paediatric LGG.
BRAF V600E-mutant PA can receive dabrafenib ± trametinib. BRAF fusion PA should NOT receive selective BRAF inhibitors (paradoxical MAPK activation) — use MEK inhibitors or tovorafenib instead.
Radiotherapy is deferred or avoided in young children due to devastating long-term effects (neurocognitive decline, secondary malignancy, endocrinopathy, vasculopathy). Reserved as last resort.
AEDs (levetiracetam) are only for supratentorial PA with seizures — NOT for cerebellar PA, and NOT for primary prophylaxis.
Multidisciplinary rehabilitation is essential: physiotherapy, speech therapy (cerebellar mutism), endocrine replacement, ophthalmology, neuropsychology.
Post-operative MRI within 24–72 hours determines GTR vs STR and guides all subsequent management decisions.

High Yield Summary — Complications of Pilocytic Astrocytoma

Obstructive hydrocephalus is the most dangerous acute complication — posterior fossa PA compresses the 4th ventricle → raised ICP → risk of tonsillar herniation and death if untreated.
Visual loss is the most important complication of optic pathway PA — often insidious in young children; optic atrophy indicates irreversible damage.
Endocrine dysfunction complicates hypothalamic PA: GH deficiency (short stature), precocious/delayed puberty, hypothalamic obesity (intractable), and rarely diabetes insipidus.
Cerebellar mutism syndrome (posterior fossa syndrome) affects ~25% of children after posterior fossa surgery — caused by bilateral dentato-thalamo-cortical tract injury; usually self-limiting but speech recovery may be incomplete.
Radiotherapy late effects are the most feared long-term complications: neurocognitive decline (2–5 IQ points/year), endocrinopathy (GH deficiency in 94%), secondary malignancy (meningioma, HGG), cerebrovascular Moyamoya (especially in NF1 patients), and ototoxicity. This is why RT is deferred/avoided in young children.
Malignant transformation is extremely rare ( < 2%) and is associated with CDKN2A/p16 loss (escape from oncogene-induced senescence). Suspect if a previously stable PA suddenly grows rapidly.
Leptomeningeal dissemination is uncommon but occurs more in optic pathway PA and the pilomyxoid variant.
Long-term survivorship issues (neurocognitive, psychosocial, endocrine, fertility) are critical because PA patients live for decades — survivorship care is as important as acute cancer treatment.

Pilocytic Astrocytoma

1. Definition

2. Epidemiology

2.1 Incidence and Prevalence

2.2 Demographics

2.3 Context in Hong Kong

3. Risk Factors

3.1 Genetic Syndromes (Most Important)

3.2 Sporadic Cases

3.3 Non-Risk Factors (Worth Mentioning)

4. Anatomy and Function – Relevant Neuroanatomy

4.1 Classical Sites of PA

4.2 Cerebellar Anatomy (Most Relevant)

4.3 Optic Pathway Anatomy

4.4 Hypothalamic Anatomy

5. Etiology and Pathophysiology

5.1 Molecular Pathogenesis — The MAPK Pathway is Central

5.1.1 BRAF Alterations (Most Common)

5.1.2 NF1 Loss (In NF1-Associated PA)

5.1.3 Other MAPK Pathway Alterations

5.2 Oncogene-Induced Senescence (OIS)

5.3 Tumour Biology Summary

6. Classification

6.1 WHO Classification of Astrocytic Tumours

6.2 Classification by Location

6.3 Related But Distinct Entity: Pilomyxoid Astrocytoma

7. Clinical Features

7.1 General Principles of Presentation

7.2 Symptoms

A. Symptoms of Raised Intracranial Pressure (Obstructive Hydrocephalus)

B. Cerebellar Symptoms (Most Common Site)

C. Optic Pathway / Hypothalamic Symptoms

D. Other Locations

7.3 Signs

A. Signs of Raised ICP

B. Cerebellar Signs

C. Optic Pathway Signs

D. Signs Related to NF1 (If Associated)

E. Endocrine Signs (Hypothalamic PA)

8. Histopathology (Brief — For Completeness)

9. Neuroimaging Appearance (Brief Preview)

MRI (Investigation of Choice)

CT (Less Preferred but Often First Done)

Active Recall - Pilocytic Astrocytoma (Definition, Epidemiology, Etiology, Classification, Clinical Features)

References

1. Framework: Why Differential Diagnosis Matters

2. Clinical Approach to Differential Diagnosis — By Presentation Scenario

Scenario A: Posterior Fossa Mass in a Child

Scenario B: Optic Pathway / Hypothalamic Mass

Scenario C: Supratentorial Mass Presenting with Seizures or Focal Deficits

Scenario D: Non-Neoplastic Mimics (All Locations)

3. Approach to Differentiating — Systematic Framework

4. Summary Table — Key Differentiating Features of PA vs Major Differentials

5. How to Narrow the DDx — "Red Flags" and Pattern Recognition

5.1 Features Favouring Pilocytic Astrocytoma

5.2 Features That Should Make You Reconsider PA

5.3 The NF1-Specific DDx

6. MRI Features Comparison — Visual Pattern Recognition

7. Age-Based DDx Summary

Active Recall - Differential Diagnosis of Pilocytic Astrocytoma

1. Diagnostic Criteria — Conceptual Framework

1.1 WHO CNS5 (2021) Integrated Diagnostic Criteria for PA

1.2 NF1 Diagnostic Criteria (Relevant When PA Presents as OPG)

2. Diagnostic Algorithm

3. Investigation Modalities — Detailed Breakdown

3.1 Neuroimaging

A. CT Brain ± Contrast

B. MRI Brain with Gadolinium Contrast (Gold Standard Imaging)

C. CT vs MRI Comparison for Brain Tumour Assessment

D. MRI Whole Neuro-axis (Craniospinal MRI)

3.2 Laboratory Investigations

3.3 Ophthalmological Assessment

3.4 Histopathology and Molecular Pathology (Gold Standard)

A. Histopathological Features

B. Molecular Pathology / Genetics

3.5 Pre-operative / Additional Investigations

3.6 Staging Investigations

4. Putting It All Together — Integration of Findings

Active Recall - Diagnostic Criteria, Algorithm, and Investigations for Pilocytic Astrocytoma

1. Principles of Management — Overview